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ANTIPSYCHOTIC DRUGS: 
REGULATING THEIR USE IN THE 
PRIVATE PRACTICE OF MEDICINE 
I. INTRODUCTION 
The discovery of a drug called chlorpromazine l marked the 
beginning of a "therapeutic"2 revolution in the practice of psy-
chiatry and the widespread use of antipsychotic drugs3 in the 
1. Chlorpromazine, a phenothiazine derivative developed in France, was introduced 
in the United States in 1953 and marketed under the brandname Thorazine. This was a 
tremendous breakthrough in psychopharmacology because chlorpromazine was found to 
have powerful sedative properties, while unlike other tranquilizers available at that time, 
it was able to tranquilize without impairing consciousness. M. LADER, INTRODUCTION To 
PSYCHOPHARMACOLOGY 56 (1980). Thorazine continues to be the most widely prescribed 
antipsychotic drug. Dubose, Of the Parens Patriae Commitment Power and Drug Treat-
ment of Schizophrenia: Do the Benefits to the Patient Justify Involuntary Treatment? 
60 MINN. L. REV. 1149, 1169 (1976); ASSEMBLY OFFICE OF RESEARCH CALIFORNIA LEGISLA-
TURE, THE USE AND MISUSE OF PSYCHIATRIC DRUGS IN CALIFORNIA'S MENTAL HEALTH PRO-
GRAMS 21 (1977) [hereinafter cited as PSYCHIATRIC DRUGS]. 
2. There continues to be controversy over psychiatry's reliance on antipsychotic 
drugs in that these drugs do not "cure" psychosis (the primary therapeutic indication 
being schizophrenia) but produce remission of psychotic symptoms rather than altering 
the course of the disorder itself. PSYCHIATRIC DRUGS, supra note I, at 14. There are those 
in the profession who feel the benefits of these drugs are exaggerated, and that since it is 
easier to prescribe drugs than try and find the reasons why a patient has developed to 
the point when the label "schizophrenia" has been given, psychiatrists are unwilling to 
try to find alternative methods of treatment. See generally, P. BREGGIN, PSYCHIATRIC 
DRUGS: HAZARDS To THE BRAIN (1983); Bierer, Medicine or "Manslaughter," 29 INT'L J. 
Soc. PSYCHIATRY 247, 248 (1983), whereupon returning from the World Congress of Psy-
chiatrists, the author labels the whole Congress as one huge Drug Factory. On the other 
hand, other psychiatrists claim that without these medications, the patient would not 
become amenable to other forms of treatment, such as psychotherapy. Brooks, The Con-
stitutional Right to Refuse Antipsychotic Medications, 8 BULL. AM. ACAD. PSYCHIATRY & 
LAW 179, 183 (1980). 
3. It has been estimated that three million Americans are currently taking antipsy-
chotic drugs, and that 925,000 new patients receive such medication each year. Gualtieri 
& Sprague, Preventing Tardive Dyskinesia and Preventing Tardive Dyskinesia Litiga-
tion, 20 PSYCHOPHARMACOLOGY BULL. 346, 347 (1984). The term "antipsychotic drug" is 
preferable to expressions· of "major tranquilizer," or "neuroleptic" because antipsychotic 
indicates the type of clinical action of these drugs. Although such a drug has a tran-
quilizing effect, it is possible that a patient can build a tolerance to the sedation, while 
the antipsychotic effects remain constant. The term neuroleptic can be considered less 
appropriate than antipsychotic as well, because it focuses on the extrapyramidal effects 
(abnormalities in motor activity) which can occur in patients receiving this drug rather 
than the clinical action. M. LADER, supra note I, at 51; L. SEIDEN & L. DYKSTRA, 
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clinical management of patients diagnosed as suffering from ma-
jor psychiatric disorders." The ability of these drugs to reduce 
the manifest symptomatology and behavioral deviances of the 
psychotic individual6 contributed greatly to the deinstitutional-
ization of the chronic psychotic and his assimilation into the 
community.6 However, these powerful drugs7 have a high 
probability of producing a wide variety of undesirable side ef-
PSYCHOPHARMACOLOGY: A BIOCHEMICAL AND BEHAVIORAL ApPROACH 198 (1977). See infra 
notes 35-58 and accompanying text for discussion of extrapyramidal effects. 
4. The major psychiatric disorders for which the use of these drugs ought to be re-
served include: schizophrenia, mania, acute organic brain syndrome (delirium), chronic 
organic brain syndrome (dementia), psychoses and behavioral problems associated with 
mental retardation and depression. Pirodsky, The Rational Use of Antipsychotic Drugs, 
in TARDIVE DYSKINESIA AND RELATED INVOLUNTARY MOVEMENT DISORDERS: THE LONG-
TERM EFFECTS OF ANTIPSYCHOTIC DRUGS 59, 60 (J. De Veaugh-Geiss ed. 1982). See id. 
(Table 6-1) for a more extensive list of indications of major psychiatric disorders. 
5. Clinically, psychotic symptoms such as anxiety, delusions, hallucinations, para-
noid ideation, catatonia, social withdrawal, and autonomic nervous system dysfunctions 
are suppressed so as to facilitate the patient's tendency and capacity for social and famil-
ial adjustment. PSYCHIATRIC DRUGS, supra note I, at 14. 
6. Deinstitutionalization was also considerably accelerated by two federal legislative 
acts in 1963. Aid to the Disabled (ATD) became available to the mentally ill. Thus psy-
chiatric patients, and mental health professionals acting on their behalf, were eligible for 
federal grants-in-aid which enabled patients to support themselves or be supported ei-
ther at home or in facilities such as board and care homes or old hotels. Money available 
to patients under ATD was sufficient to maintain a low standard of living in the commu-
nity. Consequently, it cost far less for the states to maintain patients in the community 
than in the hospital. (ATD is now administered by the Social Security Administration 
and called Supplemental Security Income or SSI). A second significant federal develop-
ment was the Mental Retardation Facilities and Community Mental Health Centers 
Construction Act, amended in 1965, which provides grants for the initial costs of staffing 
newly constructed community mental health centers. This acted as a strong incentive for 
the development of community programs to treat patients whose main resource had been 
in the state hospitals. Lamb, Deinstitutionalization and the Homeless Mentally Ill, 35 
Hosp. & COMMUNITY PSYCHIATRY 899, 902 (1984). See 42 U.S.C. §§ 1381-1385 (1982) for 
present codification of SSI for the mentally disabled. See also Mental Retardation Facil-
ities and Community Mental Health Centers Construction Act of 1963, Pub. L. No. 88-
164, §§ 200-07, 401-07, 77 Stat. 282, 290-94, 296-99, amended by Mental Retardation 
Facilities and Community Mental Health Centers Construction Act Amendments of 
1965, Pub. L. No. 89-105, §§ 220-24, 408, 79 Stat. 427, 428-30 (codified as amended in 
scattered sections of 42 U.S.C.). The number of state hospital patients in the United 
States has dropped from 559,000 in 1955 to approximately 132,000 today. See Lamb, 
supra, at 902. 
7. There are three major generic classes of antipsychotic agents. Phenothiazines 
(chief brand names are Thorazine, Mellaril, Prolixin and Stelazine); thioxanthenes (chief 
brand names Taractan and Navane); and butyrophones (chief brand name Haldol). Cal-
laway & Paull, Mental Disabilities Law Issues-Legal Awareness of Tardive Dyskine-
sia, 10 COL. LAW. 788 (M. Dice ed. 1981). See M. LADER, supra note I, at 63 (Table 5-2) 
and D. PIRODSKY, PRIMER OF CLINICAL PSYCHOPHARMACOLOGY: A PRACTICAL GUIDE (1981) 
reprinted in Pirodsky, supra note 4, at 63 (Table 6-3) for a more extensive classification 
of most of the antipsychotics currently available in the U. S. 
2
Golden Gate University Law Review, Vol. 15, Iss. 2 [1985], Art. 3
http://digitalcommons.law.ggu.edu/ggulrev/vol15/iss2/3
1985] REGULATING ANTIPSYCHOTIC DRUGS 333 
fects. 8 In a generally unsuccessful attempt to improve the thera-
peutic ratio between wanted and unwanted side effects, over 
thirty different antipsychotic drugs of differing chemical struc-
tures have been introduced into the market.9 
The manifest risk that the administration of antipsychotic 
drugs may lead to harmful side effects, as well as alarming evi-
dence in some cases of negligent and abusive medication prac-
tices in state institutions,IO has motivated courts to hold that in-
voluntarily committed patients have a qualified constitutional 
right to refuse antipsychotic medication.ll Although antipsy-
8. Taub, Psychiatric Malpractice in the 1980's: A Look at Some Areas of Concern, 
11 LAW, MEDICINE, & HEALTH CARE 97,102 (I983). See infra notes 31-69 and accompany-
ing text for a discussion of these side effects. 
9. Blackwell, Schizophrenia and Neuroleptic Drugs: A Biopsychosocial Perspective, 
in REFUSING TREATMENT IN MENTAL HEALTH INSTITUTIONS - VALUES IN CONFLICT 13, 15 
(A. Doudera & J. Swazey eds. 1982) [hereinafter cited as VALUES IN CONFLICT). This text 
is a compilation of papers and discussions derived from a national conference by the 
same name in November 1980; M. LADER, supra note I, at 63. The drugs still in use are 
those that have been available the longest. Blackwell, supra, at 15. 
10. See Rogers v. Comm'r of the Dept. of Mental Health, 390 Mass. 489 _, 458 
N.E.2d 308, 320-21 (1983) (citing literature and cases where antipsychotic medication 
has been found to be used for the convenience of the staff rather than treatment); 
Brooks, supra note 2, at 188-89. Antipsychotic drugs may also be used to compensate for 
personnel shortages in that administering drugs only takes a few minutes of professional 
time, as well as being inexpensive in comparison to having adequate staffing levels. Rog-
ers, 390 Mass. at __ , 458 N.E.2d at 318 n.19; L.A. Daily J., May 16, 1983, at I, col. 4. It 
has also been asserted that pro re nata prescriptions (according as the circumstances 
may require) which allow nurses and technicians to determine the need for antipsychot-
ics from a doctor's open-ended prescription may be used for punishment or control of 
patients by staff members not adequately trained to make treatment decisions. Bishop, 
The Expanding Rights of Mental Patients, 2 CAL. LAW., Sept. 9, 1982 at 108. 
11. See Rennie v. Klein, 653 F.2d 836, 844-45 (3d Cir. 1981), vacated and remanded, 
458 U. S. 1119 (1982) aff'd, 720 F.2d 266 (3d Cir. 1983) (patient has a constitutional right 
to be free from treatment that poses substantial risks to his well-being); Rogers v. Okin, 
634 F.2d 650, 653 (1st Cir. 1980), cert. granted, 451 U.S. 906 (1981), vacated and re-
manded sub nom., Mills v. Rogers, 457 U.S. 291 (1982), aff'd on other grounds, Rogers v. 
Comm'r of the Dept. of Mental Health, 390 Mass. at __ , 458 N.E.2d at 308 (constitu-
tionally protected interest in being left free by the state to decide whether to submit to 
the serious and potentially harmful medical treatment that is represented by the admin-
istration of antipsychotiC drugs); Project Release v. Prevost, 722 F.2d 960 (2nd Cir. 1983) 
(constitutional liberty interest in refusing antipsychotic medication); JanIison v. Farabee, 
No. C 780445, WHO (N.D. Cal. April 26, 1983) (settlement approved by federal district 
court judge recognized that mental patients have a substantial right to refuse medica-
tion); Colorado ex rei. Medina, 662 P.2d 184 (Colo. Ct. App. 1982); Anderson v. Arizona, 
135 Ariz. 578, 663 P.2d 570 (1982) (concluded that right to refuse medication based on 
state statute exceeded constitutional minima). Although the above cases all acknowl-
edged a qualified constitutional right to refuse" antipsychotic medication, the decisions 
differed in the standards and procedures employed to protect the involuntarily commit-
ted patient's right when determining when the state may override a patient's refusal. 
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chotic drugs may be beneficial,12 the fact that harmful side ef-
fects do occurlS warranted the court's intervention to protect in-
voluntarily committed patients. The rationale being that this 
harm was being imposed by the exercise of the state's police 
power in deciding to involuntarily commit a patient.14 
In addition to affording the involuntarily committed patient 
a right to refuse, these litigations, III along with legislative inquir-
iesl8 and newspaper accounts,17 revealed that improper, exces-
sive, or inappropriate use of antipsychotic medication frequently 
occurred in psychiatric hospitals and institutions in the public 
sector.18 Consequently, a number of states have taken affirma-
See, e.g., Rennie v. Klein, 720 F.2d at 269 (medication refusal can only be overcome if, in 
the exercise of professional judgment, administration of antipsychotics is necessary to 
prevent the patient from endangering himself or others); Roger v. Comm'r of the Dept. 
of Mental Health, 390 Mass. at _, 458 N.E.2d at 321-22 (medication refusal can only be 
overridden in an emergency when the patient poses imminent threat of harm to himself 
or others, or to prevent immediate, substantial, and irreversible deterioration of a serious 
mental illness, and where a patient has been specifically ajudicated incompetent to make 
treatment decisions, a substitute judgment by way of court approval is necessary to over-
ride the patient's objection); Jamison v. Farabee, supra (medication refusal overridden 
in the event of either: 1) an emergency; 2) the patient is substantially deteriorating; or 3) 
upon approval of an independent reviewer where court appointed conservator). Portions 
of the Jamison settlement and exhibits reprinted in California Consent Decree Gives 
Right to Refuse Antipsychotic Medication, 7 MENTAL DISABILITY L. REP. 437 (1983). 
12. A study by the National Institute of Mental Health found that 75% of the pa-
tients treated with antipsychotic drugs showed marked degrees of improvement within 
six weeks after being hospitalized, while only 23% of the placebo groups were rated as 
showing marked or moderate improvement. Roth & Appelbaum, What We Do and Do 
Not Know About Treatment Refusals in Mental Institutions, in VALUES IN CONFLICT. 
supra note 9, at 179, 182-83. 
13. Dangerous side effects occur even where anti psychotics are prescribed and ad-
ministered in accordance with competent and responsible clinical practice. However, the 
distress on the part of the patients as a result of these side effects may be significantly 
worse where these drugs are administered negligently or abusively. Brooks, supra note 2, 
at 183. See infra notes 65-69 and accompanying text. 
14. Consequently, the courts were required to pursue their traditional role of ensur-
ing the individual is protected against harmful state interventions without regard to the 
state's good intentions in deciding that hospitalization is necessary to provide cure and 
treatment. Brooks, supra note 2, at 182. 
15. See supra note 11. 
16. See, e.g., PSYCHIATRIC DRUGS, supra note 1 (legislative investigation finding 
large-scale irrational prescribing and administration of antipsychotic medication in Cali-
fornia's mental health programs) and New York Commission Finds Significant Problems 
in Psychotherapeutic Drug Usage in State Mental Hospitals, 8 MENTAL & PHYSICAL 
DISABILITY L. REP. 139 (1984). 
17. See, e.g., Sobel, Psychiatric DruglJ Widely Misused, Critics Charge, N.Y. Times, 
June 3, 1980, at C1, col. 5. 
18. Brooks, supra note 2, at 183. See supra note 10. 
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tive action imposing antipsychotic medication guidelines19 in an 
effort to minimize the temptation of staff to abuse the "manage-
ment" potential of these drugs for their own convenience in 
state facilities. 
These safeguards being implemented in state facilities, how-
ever, only serve to monitor medication regimens of a relatively 
small number of individuals in comparison to the numbers who 
receive antipsychotic drugs outside of state institutions.20 Fur-
thermore, the exodus of the chronic mentally ill into the com-
munity as a result of deinstitutionalization placed many of these 
individuals outside the closed environment of any hospital.21 
19. E.g., the New York State Office of Mental Health has established clinical policy 
on the appropriate methods of prescribing and administering drugs for patients in facili-
ties within the jurisdiction of the Office of Mental Health. The guidelines have been 
incorporated into a computerized drug ordering system and a computerized drug excep-
tion system for automated review. COMMI'ITEE ON THERAPEUTICS, N.Y. STATE OFFICE OF 
MENTAL HEALTH, PSYCHOTHERAPEUTIC DRUG MANUAL (2d ed. 1981). See Laska, Siegel & 
Simpson, Automated Review System for Orders of Psychotropic Drugs, 37 ARCH GEN. 
PSYCHIATRY 824-27 (1980) for a further explanation of the operation of this drug excep-
tion system which acts as a check on improper drug therapy. Texas state mental hospi-
tals are now required to administer psychotropic drugs according to a set of guidelines 
established pursuant to a settlement approved by a federal district court. R.A.J. v. 
Miller, No. C-A-3-74-394-M (N.D. Tex. Feb. 14, 1983). See Am. Med. News, March 4, 
1983, at 24, col. 2 for a discussion of these guidelines. In California, pursuant to JanIison 
v. Farabee, No. C780445 WHO (N.D. Cal. April 26, 1983) a Therapeutic Review Commit-
tee was established to review medication decisions that fall outside drug guidelines de-
termined by a Sub-Committee of the Therapeutic Review Committee. Although the set-
tlement applied to one state hospital (Napa State Hospital), the terms of the agreement 
provided that after a one year pilot of having a Therapeutic Review Committee at Napa, 
such a uniform drug monitoring system would extend to all state facilities in April 1985. 
Telephone interview with Dr. Steve Schone, Deputy Director of Clinical Services, Cal. 
Dept. of Mental Health (November 6, 1984). 
20. The dimensions of this problem are revealed by the numbers. Although it is 
estimated that three million Americans are receiving antipsychotic drugs, only approxi-
mately 132,000 of these individuals are patients in state hospitals. See supra notes 3 and 
6. 
21. In the initial years following deinstitutionalization in the 1960's, approximately 
two thirds of discharged mental patients aged 18 to 65 returned home to their fanIilies. 
In states which have a nigh number of persons who are without fanIilies (which is the 
case in California), this figure is probably closer to 50 percent. LanIb, supra note 6, at 
902. Many of those over 65 years old failed to survive the trauma of the transfer from 
state hospitals to nursing homes. See generally, P. AHMED & S. PLOG, STATE MENTAL 
HOSPITALS, WHAT HAPPENS WHEN THEY CLOSE (1976). Today a large proportion of the 
chronic psychotic population aged 18 to 65 live in community facilities such as board and 
care homes. Lamb, supra note 6, at 903. One repercussion of leaving a closed hospital 
environment is that if a person is being maintaIned on a drug regimen contrary to good 
clinical practice, the likelihood that inappropriate prescribing will be noticed appears far 
greater in the closed environment of a hospital. See PSYCHIATRIC DRUGS, supra note I, at 
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This is of particular importance because it is the chronic men-
tally ill who often are ultimately the most susceptible to irre-
versible side effects as the result of extended drug exposure.22 
Given psychiatry's continued reliance on antipsychotic drugs as 
a major mode of treatment for many chronically ill individuals,23 
and the apparently unavoidable propensity of these drugs to 
produce side effects, it is essential that these drugs be prescribed 
cautiously only to those individuals who absolutely require 
them. Thus, similar safeguards in insuring that the safest and 
most efficient medication procedures are being followed in the 
18. 
22. See infra notes 50, 51, 56 and accompanying text. Also, the value of antipsy-
chotic medication to treat the chronically mentally ill, as opposed to treating acute pa-
tients, is not as clear, in that the harm resulting from the medication outweighs the 
benefit for a significant number of medicated persons. See infra notes 17-28 and accom-
panying text for drug efficiency in treating acute patients and infra note 29 for the effi-
ciency of continued antipsychotic medication in chronic patients. 
23. Published guidelines, scientific articles, presentations at professional meetings, 
and warnings in the Physicians' Desk Reference (a drug industry publication which re-
peats the information given in the package inserts) addressing one of the most troubling 
side effects called tardive dyskinesia (a potentially irreversible side effect characterized 
by rhythmical involuntary movements of the tongue, face, mouth, jaw, and extremities) 
appear to have had minimal effect on actual physician behavior in prescribing antipsy-
chotic drugs. Gualterieri & Sprague, supra note 3, at 347. See infra notes 44-58 and 
accompanying text for a discussion of tardive dyskinesia. There has been no measurable 
decline in the number of antipsychotic prescriptions: 17 to 19 million in 1973, the same 
number in 1983. Gualterieri & Sprague, supra at 347. One can only speculate the under-
lying reasons for psychiatry's reluctance to depart from what had once been regarded as 
customary and uncontroversial treatment for major psychiatric disorders. Brooks, supra 
note 2, at 182. It has been suggested that the practice of psychiatry is intricately tied to 
the drug industry because of its prevailing influence on the practice of medicine. For 
example, medical journals are funded to a large extent by drug companies (one can pick 
up most any medical journal and see extensive advertising by the competing drug com-
panies). Drug companies also sponsor seminars and research on aspects of psychiatric 
care and the use of drugs. PSYCHIATRIC DRUGS, supra note 1, at 28. See P. BREGGlN, supra 
note 2, at 256-59 for a further discussion of psychiatric dependence on drug companies. 
Psychiatrists may also be influenced by drug salespersons (detail men) who make peri-
odic calls on physicians, pharmacists and hospital purchasing agents offering free sam-
ples to promote their firm's products. Dr. Dale Console, Medical Director for the E. R. 
Squibb pharmaceutical company testified during federal hearings that "[t]he primary 
purpose of the detail man is to make a sale even if it involves irrational prescribing and 
irrational combinations. During my time in the drug industry, I had a close ongoing rela-
tionship with detail men. It was from them that I learned the simple maxim, 'If you can't 
convince them, confuse them.' " PSYCHIATRIC DRUGS, supra at 28. It has also been sug-
gested that with the advances in medicine and its growing technology, society has come 
to expect that medicine can put an end to all suffering. In psychiatry, psychiatric drugs 
in many cases stand as the sole vehicle of health delivery fitting into this fantasy. The 
psychiatrist, caught between priorities placed on rapid, effective treatment and his need 
to appear masterful, may be attempting to solve problems which go beyond the realm of 
medicine by prescribing only partially effective medication. Id. at 29. 
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treatment of the chronic mentally ill in the private sector of 
clinical practice are mandated. 
This Comment will address the problems of antipsychotic 
drug usage in two areas in which the private practice of psychia-
try is involved: nursing homes and board and care homes. Al-
though each of these areas present an entirely different set of 
problems, and concern different age groups, they both serve 
functions which had traditionally been that of the state hospi-
tals before de institutionalization - treating the chronic men-
tally ill. Before considering the use of antipsychotic medication 
in nursing homes and board and care homes,24 the risk of side 
effects as a result of these drugs will be examined. It will be 
shown that negligent and even abusive use of these drugs occurs 
in the private practice of medicine, necessitating some type of 
medication regulation similar to that which is occurring in the 
public sector. The rights of doctors will also be addressed in con-
junction with the state's authority to intervene in the private 
practice of medicine. 
24. The use of these drugs in these two areas, will specifically refer to practices in 
California, although similar practices are as likely to occur in nursing homes and board 
and care homes in other states as well. It is beyond the powers of the federal government 
to enact any regulations directly regulating the health, safety and welfare of the citizens 
within the borders of any given state. Any intervention pertaining to the administration 
of antipsychotic drugs would be left up to the discretion of state governments, and thus 
vary from state to state. California has not only taken the initiative to implement medi-
cation review in state facilities (see supra note 19) but also a medication monitoring 
system for all county operated and county contracted mental health facilities. The 
county quality assurance system provides for review of the appropriateness of the medi-
cations prescribed, the appropriateness of dosage levels, the effectiveness of the medica-
tion for the client, and the occurrence of any adverse reactions. CAL. HEALTH & SAFETY 
CODE § 5624(c) (West 1982). This statute is enforced by monitoring a 10% patient sam-
ple of each county physician, on the theory that if a physician is accustomed to prescrib-
ing medication irrationally it will be detected. Also the mere fact that a random 10% of a 
physician's caseload will be monitored is sufficient in deterring inappropriate medication 
administration for all patients. Telephone interview with Mike Writer, Pharmacy Coor-
dinator, Community Mental Health Administration of San Francisco (October 17, 1984). 
Therefore, since California has regulated the use of antipsychotic drugs to such an extent 
in the public sector, the remaining issue to be addressed is the need for regulation in 
private practice as well. (The actual efficiency of California's attempt to curb negligent 
or abusive use of these drugs in state and county facilities is an entirely different issue 
beyond the scope of this Comment. What is important is that the problem has been 
recognized and steps are being taken to remedy the problem). 
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II. BACKGROUND 
A. The Effects of Antipsychotic Drugs 
The first important use of antipsychotic drugs was to reduce 
psychomotor excitement, severe agitation, or disturbed behavior 
by taking advantage of their sedative effects.211 This clinical ef-
fect was utilized to manage those patients who became irritable 
with minimal provocation and became combative towards nurs-
ing staff and other patients in the hospital unit.26 However, the 
main indication for antipsychotic drugs today is the treatment 
of acute schizophrenia.27 Although these drugs only suppress the 
25. M. LADER, supra note I, at 56. The drugs have symptomatic tranqualization ef-
fects on target symptoms, a term that emphasizes the drug effects on symptoms irrespec-
tive of diagnosis. For example, in patients with schizophrenia such drugs reduce restless-
ness, excitement, paranoid tension, panic, aggressive outbursts, stereotyped behavior 
(occurrence of repeated sequence of motor responses), and noisy destructive behavior. Id. 
See id. for target symptoms of other illnesses. 
26. Patients diagnosed as psychotic or as having chronic organic brain syndrome 
(dementia) are the most likely to become assaultive or belligerent in moments of panic or 
hostility. M. LADER, supra note I, at 56; Pirodsky, supra note 4, at 61. However, not all 
patients manifest symptoms of their illness in a hostile manner. Patients may exhibit 
marked symptoms of psychosis by becoming antisocial and withdrawn as well. L. SEIDEN 
& L. DYKSTRA. supra note 3, at 198. Although the use of these drugs in this manner may 
be viewed as a "chemical straitjacket," it has become a widely established practice. M. 
LADER. supra, at 56. Such medication is also helpful in decreasing hallucinations, emo-
tional flattening (inappropriate effect), withdrawn behavior, sleep disturbance, as well as 
improving thought disorder. Id.; Pirodsky, supra note 4, at 60; Roth & Appelbaum, 
What We Do and Do Not Know About Treatment Refusals in Mental Institutions, in 
VALUES IN CONFLICT. supra note 9, at 182-83. There is also evidence that the earlier the 
drug treatment the more likely rehabilitation will persist up to five years after release. 
Roth & Appelbaum. Id. at 183. However, this lasting effect may be the result of shorten-
ing the patient's length of stay in the hospital, and thereby avoiding what has come to be 
known as institutionalism (syndrome characterized by lack of initiative, apathy, submis-
siveness to authority and extreme dependence on the institution), rather than a specific 
ongoing pharmalogical effect of the medication. Id.; Cole, Patients' Rights v. Doctors' 
Rights: Which Should Take Precedence? in VALUES IN CONFLICT. supra note 9, at 59; 
Lamb, supra note 6, at 900. 
27. M. LADER. supra note 1, at 56. Schizophrenia refers to disorders in mood 
(marked by either the absence of emotional display or heightened emotional reactions 
termed inappropriate affect), behavior (manifestations include extreme withdrawal or bi-
zarre activities such as remaining in one rigid position for hours at a time termed cata-
tonic rigidity), and thought (fixed false beliefs called delusions, disturbed use of lan-
guage, hallucinations, the most common being auditory, and attentional problems). L. 
SEIDEN & L. DYKSTRA. supra note 3, at 198; AMERICAN PSYCHIATRIC ASSOCIATION. DIAG-
NOSTIC & STATISTICAL MANUAL OF MENTAL DISORDERS. 181-84 (3rd ed. 1980). See id. at 
181-93 for a complete clinical classification of this group of disorders and diagnostic 
categories. 
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symptoms of schizophrenia, they often prevent the progression 
of the condition both by cutting short the initial acute attack of 
thought disorder and subsequent relapses.28 Evidence of the 
benefits of antipsychotic drugs for the chronic mentally ill, how-
ever, is not conclusive.29 Thus, the necessity or effectiveness 
must be clearly established, and weighed against the risk of 
long-term side effects, before committing an individual to treat-
ment with anti psychotics for more than a few months.30 
28. M. LADER, supra note 1, at 57. See supra note 12. The experimental literature 
has been summarized as revealing that 60 % -70 % of acute schizophrenics on no drugs are 
readmitted within one year, compared with 20%-30% who receive some form of drug 
therapy. G. Crane, Clinical Psychopharmacology in Its 20th Year, 181 SCI. 124, 125 
(1973). See Dubose, supra note I, at 1170-1202 for an extensive review of the experimen-
tal literature assessing the benefits of antipsychotic medication in the treatment of 
schizophrenia. 
29. Brooks, supra note 2, at 183. There is a wide range of reported results in the 
literature on rehospitalization rates, comparing patients maintained either on drugs or 
on placebos. A review of 30 studies addressing the efficiency of continued antipsychotic 
medication in preventing psychotic relapse in chronic schizophrenia patients found 
nearly half of the chronic patients receiving a placebo did not deteriorate within a year. 
Tardive Dsykinesia: Summary of Task Force Report of the American Psychiatric Asso-
ciation, 137 AM. J. PSYCHIATRY 1163, 1167 (1980) [hereinafter cited as APA)]. Thus, for 
those patients who did not experience a relapse while receiving a placebo, it appears that 
there would not have been any clearcut benefit from having continued to take antipsy-
chotic drugs. Another study making this comparison found reported differences in the 
rehospitalization rate between drug and placebo patients ranged from 12% to 59%. PSY-
CHIATRIC DRUGS, supra note 1, at 14. A review of 40 studies on patient deterioration after 
termination of the drugs reached the conclusion that no determination of the drug's ef-
fectiveness could be drawn because of methodological flaws in the studies they reviewed. 
Id. The fact that these studies focusing on chronic schizophrenia evaluate outcome at 
varying times may also explain this uncertainty. The longer the time after recovery or 
the more chronic the illness becomes, the harder it is to demonstrate that treatment with 
antipsychotic drugs makes any significant difference. Comment, Madness and Medicine: 
The Forcible Administration of Psychotropic Drugs, 1980 WIS. L. REV. 497, 540 n.188 
(1980) [hereinafter cited as Comment, Madness & Medicine]. See id. at 539-40, nn.185-
91 and Note, A Common Law Remedy for Forcible Medication of the Institutionalized 
Mentally Ill, 82 COLUM. L. REV. 1720, 1725, nn.52-57 (1982) for further studies offering 
conflicting conclusions. 
30. APA, supra note 29, at 1167. Such a decision to continue treatment requires: (1) 
more than one acute psychotic episode without full return to prepsychotic status, (2) 
objective evidence of continuing psychosis, or (3) recovery but frequent recurrences that 
suggest the likelihood of future relapses, and (4) evidence of responsiveness to treatment. 
Id. It is essential that after a first acute psychotic episode of any type has cliinically 
remitted, the dosage should be gradually decreased and discontinued within several 
months because many acute episodes eventually prove to be episodes of manic-depres-
sive illness, which has not been proven scientifically to benefit from continued antipsy-
chotic treatment. Id. at 1168. It has been asserted that therapists may continue adminis-
tration of those drugs without considering the possibility of naturally occurring 
remissions. Thus, the choice of drug regimen may be determined more by the severity of 
a previous episode, than by a patient's current status. Crane, supra note 28, at 125. 
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Many of the physical side effects which arise in conjunction 
with administration of these drugs are relatively "minor"31 and 
are reversible if the medication is discontinued.32 Such common 
adverse reactions include: drowsiness, nausea, constipation, un-
controllable restlessness, dizziness, faintness, blurred vision, dry 
mouth, significant weight gain, and altered eye and skin pigmen-
tation.33 In addition these medications often cause loss of sexual 
drive; males may even be unable to ejaculate, and in females 
swelling of the breast, spontaneous lactation, and menstrual ir-
regularities due to blockage of ovulation may occur.3" Other un-
wanted effects, perhaps even more disturbing for the patient, are 
frequently caused abnormalities in motor activity, called ex-
trapyramidal effects.81i 
The earliest extrapyramidal effect to develop is acute dys-
tonia characterized by spasmodic muscle contractions of the 
tongue, face, neck, and back.86 This side effect can be quickly 
reversed by either the administration of an antiparkinsonian 
agent,87 or diazepam (an anti-anxiety agent),88 or by reduction or 
31. While these adverse reactions may be viewed as mild by clinical standards on 
the part of the psychiatrist, they are often extremely distressing to the patient. PSYCHI-
ATRIC DRUGS, supra note I, at 16. See Comment, Madness & Medicine, supra note 29, at 
536 n.178 for a personal account of a former mental patient. 
32. However, for many chronic patients on maintenance antipsychotic therapy, 
these side effects are permanent in that they invariably accompany the continued intake 
of medication. Brooks, supra note 2, at 187. 
33. M. LADER, supra note I, at 59, 62; PSYCHIATRIC DRUGS, supra note I, at 16; 
Brooks, supra note 2, at 184; Comment, Madness & Medicine, supra note 29, at 535 
n.177. Pigmentary changes in the skin and eye is a long-term side effect, mainly with 
chlorpromazine (Thorazine), caused by the accumulation of drugs and their metabolites 
and pigments in the cornea, lens and skin. The skin becomes extremely sensitive to sun-
light and exposure to the sun leads to a purple-gray discoloration. The eyes become 
opaque. This opacity may persist for as long as six months after termination of drug 
therapy. M. LADER, supra at 62; Dubose, supra, note I, at 1204. See Blackwell, supra 
note 9, at 16 for an extensive list of unwanted effects of these drugs. 
34. PSYCHIATRIC DRUGS, supra note I, at 16; Brooks, supra note 2, at 184; Comment, 
Madness & Medicine, supra note 29, at 535. These effects are due to the antipsychotic 
medication suppressing activity of the hypothalamus, an area of the brain which regu-
lates the secretion of hormones. [d. 
35. M. LADER, supra note I, at 59. 
36. Callaway & Paull, supra note 7, at 788; M. LADER, supra note I, at 59; APA, 
supra note 29, at 1164. A few doses or even a single dose of the antipsychotic drug may 
be sufficient to induce the condition, and has been found to most likely occur in males 
and in children. M. LADER, supra, at 59. These muscle spasms may mimic seizures. APA, 
supra, at 1164. 
37. Unimpaired motor activity is the result of a delicate balance between two bio-
genic amines (neurotransmitters) in the basal ganglia of the brain: dopamine which acts 
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withdrawal from medication.89 Another extrapyramidal effect is 
akathisia, an uncontrollable physical restlessness as well as a 
strong subjective sense of restlessness, characterized by the in-
ability to sit still."o Although this side effect is most likely an 
indication that the drug dosage needs to be reduced, it may eas-
ily be mistaken for increasing psychotic tension, anxiety or agi-
tation."l The most common extrapyramidal effect is akinesia, 
characterized by physical immobility and lack of spontaniety."2 
as a motor activity inhibitor and acetylcholine which acts as a motor activity facilitator. 
Comment, Madness & Medicine, supra, note 29, at 531 n.56. Antipsychotic drugs are 
believed to block the reception of dopamine, resulting in a decrease of dopamine which is 
responsible for producing the drugs' antipsychotic effect. (It is hypothesized that schizo-
phrenia is "caused" by an excess of dopamine activity). M. LADER, supra note I, at 59. 
However, by decreasing dopamine activity, an overbalance of acetylcholine occurs, pro-
ducing the extrapyramidal effects. True parkinsonism is due to the naturally occurring 
lack of dopamine, and accordingly L-dopa, the metabolic precusor of dopamine, is used 
in treatment to increase dopamine levels to correct the overbalance of acetylcholine. L. 
SEIDEN & L. DYKSTRA. supra note 3, at 135. But since psychosis is thought to be the 
result of excessive dopamine, L-dopa would aggravate schizophrenia. Id. Antiparkinson-
ism drugs (anticholinergic drugs), instead of correcting the overbalance of acetycholine 
by increasing dopamine activity, decreases the activity of acetycholine to balance with 
the antipsychotic drug-induced lower levels of dopamine. Madness & Medicine, supra, 
at 531 n. 156. Anticholinergic drugs, however, produce their own side effects such as dry 
mouth, blurred vision, nausea, nervousness, and mental confusion. Id. Also, antiparkin-
sonism drugs are not effective in the prevention of extrapyramidal symptoms, but only in 
treatment once they occur. M. LADER, supra, at 60; Pirodsky, supra note 4, at 68-69. 
38. M. LADER, supra note I, at 59. 
39. Id. at 60; Callaway & Paull, supra note 7, at 788; Pirodsky, supra note 4, at 68. 
Reduction or withdrawal of antipsychotic medication is preferable to avoid increasing 
susceptability to tardive dyskinesia. M. LADER, supra, at 60. See infra note 47 for an 
explanation of why the combination treatment of anti parkinsonian medication and anti-
psychotics should be avoided. 
40. APA, supra note 29, at 1164; M. LADER, supra note I, at 59. One study found 
that patient reluctance to take antipsychotic drugs was most notably associated with the 
patient's fear of akathisia or what has been referred to as the "syndrome of impatience." 
Patients often experience fright or terror at this compulsion to move. Van Putten, Why 
Do Schizophrenic Patients Refuse to Take Their Drugs, 31 ARCH. GEN. PSYCHIATRY 67, 
71 (1974). 
41. APA, supra note 29, at 1164; M. LADER, supra note I, at 59. Due to the fact that 
the extrapyramidal manifestation is entirely subjective and in its milder form it may be 
almost impossible to distinguish from symptomatic anxiety of psychosis. Van Putten, 
supra note 40, at 71. Misdiagnosing akathisia as a psychotic symptom may lead to an 
increase in the dosage of medication prescribed. With akathisia, antiparkinsonian drugs 
are usually ineffective, but a benzodiazepine (an anti-anxiety drug) may help treat the 
restlessness. M. LADER, supra, at 59; APA, supra, at 1164. 
42. Callaway & Paull, supra note 7, at 788; Brooks, supra note 2, at 184. Akinesia 
also effects fine-movement control manifested by small handwriting, a useful sign of this 
side effect. M. LADER, supra note I, at 60. There are treatment-resistent cases of drug-
induced parkinsonism in chronic drug-treated patients despite usual antiparkinsonian 
drug treatment. Gardos & Cole, Overview: Public Health Issues in Tardive Dyskinesia, 
137 AM. J. PSYCHIATRY 776, 779 (1980). 
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This is caused by the drug weakening those muscles used in re-
petitive actions such as walking, and more severely affected pa-
tients show signs of drug-induced parkinsonism.43 
The most serious extrapyramidal effect produced by antip-
sychotics is tardive dyskinesia, a potentially irreversible condi-
tion44 characterized by involuntary muscle movements, particu-
larly those of the face, mouth, and limbs.411 In its most 
progressive state, the condition interferes with all motor activity, 
making speech incomprehensible and breathing and swallowing 
extremely difficult.46 Unlike other neurologic side effects there is 
generally no effective treatment of tardive dyskinesia;" 
43. Signs of drug induced parkinsonism are a loss of associated movements: muscu-
lar rigidity, tremor, stooped posture, masked expression, shuffling gait, and excessive sal-
ivation and seborrhoea. M. LADER, supra note I, at 60; APA, supra note 29, at 1163-64. 
Women, particularly the elderly, are the most commonly affected, and the incidence of 
parkinsonism is about 15% -25% among patients being treated with moderate doses of 
anti psychotics. M. LADER, supra, at 60. 
44. M. LADER, supra note I, at 61. In about half of the patients who already mani-
fest tardive dyskinesia, the condition persisted even after withdrawal from the medica-
tion. [d. A review of 23 treatment studies in which anti psychotics were withdrawn for 
periods varying from several weeks to three years revealed that 36.5 % had a remission of 
dyskinesia symptoms. These studies also indicated that presence of tardive dyskinesia 
three months after discontinuation of antipsychotic drugs may be a valid criteria for 
irreversible dyskinesia. Jeste & Wyatt, Therapeutic Strategies Against Tardive Dys-
kinesia: Two Decades of Experience, 39 ARCH. GEN. PSYCHIATRY 803, 812 (1982). It 
should be noted, however, that the low rates of reversibility in these discontinuation 
studies may be confounded by the rate of patient dropout due to psychiatric (usually 
schizophrenia) deterioration which can limit the follow-up time after discontinuation. 
Furthermore, these studies often involve patients who have histories of long antipsy-
chotic drug exposure, so that the results may also be confounded by the duration of the 
tardive dyskinesia itself. Glazer, Moore, Schooler, Brenner & Morgenstern, Tardive Dys-
kinesia: A Discontinuation Study, 41 ARCH. GEN. PSYCHIATRY, 623, 625 (1984). 
45. Roth & Appelbaum, supra note 12, at 185. An inability to keep the tongue ex-
truded, and a quivering of the tongue on the floor of the mouth are some of the earliest 
signs of tardive dyskinesia. M. LADER, supra note I, at 61. The patient may exhibit such 
involuntary movements as repeated sucking and smacking of the lips, darting of the 
tongue, blowing of the cheeks, and side to side movements of the jaw. PSYCHIATRIC 
DRUGS, supra note I, at 16; Crane, supra note 28, at 127. 
46. Crane, supra note 28, at 127; Callaway & Paull, supra note 7, at 788; Gardos & 
Cole, supra note 42, at 777. 
47. Munetz, Roth & Comes, Tardive Dyskinesia and Informed Consent: Myths and 
Realities, 10 BULL. AM. ACADEMY PSYCHIATRY L. 77 (1982); APA, supra note 29, at 1168. 
The treatment of tardive dyskinesia has been hindered by the fact that the specific cause 
of this side effect is unknown. Since it is believed that antipsychotic drugs block the 
reception of dopaminergic neurotransmitters, the prevailing explanation for tardive dys-
kinesia is the "dopamine supersensitivity" hypothesis. Antipsychotic drugs are not capa-
ble of selectively blocking all dopamine receptors, thus under this hypothesis, after con-
tinued administration of these drugs, those receptors which have not been blocked 
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Tardive dyskinesia is the center of much controversy in psy-
chiatric treatment for several other reasons. First, there is no set 
duration of antipsychotic drug exposure before the dyskinesia 
occurs.·8 Although, as the name implies, it was originally 
thought only to appear late in patients who had been receiving 
long-term treatment,·e it has been reported to occur after only a 
few months of treatment.llo This unpredictability is further con-
become hyperactive in an attempt to compensate for the receptors which are being 
blocked, resulting in excessive dopaminergic activity, causing the dyskinesic symptoms. 
Consequently, withdrawal makes the condition worse because even more receptors be-
come active, adding to the already overabundance of dopaminergic activity, and if anti-
psychotic drugs are reinstated or the dose raised, this merely postpones the dyskinesia 
because eventually the supersensitivity of those receptors still remaining active increases, 
again causing dyskinesia. Antiparkinsonism medication worsens the condition because 
these drugs induce drug-metabolizing enzymes in the liver, which results in decreased 
plasma antipsychotic drug concentrations, leading to greater dopamine activity. Also, by 
decreasing the activity of acetylcholine (see supra note 37), the existing balance between 
acetylcholine and dopamine is overbalanced towards greater activity of dopamine. M. 
LADER, supra note I, at 60-62. This finding has implicated routine administration of an-
tiparkinsonism drugs as predisposing the patient to tardive dyskinesia. Yassa, Ananth, 
Cordozo, & Ally, Tardive Dyskinesia in an Outpatient Population: Prevalence and 
Predisposing Factors, 28 CAN. J. PSYCHIATRY 391, 394 (1983); see generally Jeste & Wy-
att, supra note 44 for an extensive review of varying experimental treatment modes for 
tardive dyskinesia. Those studies which purport to have found an effective treatment for 
tardive dyskinesia should be interpreted cautiously. Statistically significant changes in 
improvement may not be synonymous with clinically meaningful improvement. For ex-
ample, assume the mean amount of improvement resulting from a treatment when com-
pared with a baseline is 25%-30%, yielding statistically significant results when a suffi-
cient number of patients are studied. However, at the same time these patients showing 
improvement retain 70%-75% of their original dyskinesic symptoms. Also, the factor of 
dropouts are frequently ignored in data analysis. When patients who fail to complete a 
trial due to lack of improvement, side effects, or worsening of their primary psychiatric 
condition are excluded from the final analysis, the reported results are actually not as 
positive as they appear. [d. at 805. 
48. In a review of 56 tardive dyskinesia studies, out of the 21 studies exploring the 
length of drug treatment, 15 studies found no significant relationship between length of 
antipsychotic drug exposure and this condition. Six studies, on the other hand, found the 
length of treatment to be a significant factor; two of which involved patients who had 
been exposed to these drugs for brief periods. Kane & Smith, Tardive Dyskinesia: Prev-
alence and Risk Factors, 1959 to 1979, 39 ARCH. GEN. PSYCHIATRY 473, 476 (1982). 
49. The dyskinesia typically takes several'years to appear. A substantial percentage 
of patients who develop tardive dyskinesia manifest it within three years of drug expo-
sure. However, since dating the emergence of tardive dyskinesia retrospectively is diffi-
cult, studies indicating the occurrence of symptoms to be within 18 months to three 
years may be conservative. [d.; M. LADER, supra note 1, at 61; Roth & Appelbaum, supra 
note 12, at 186. 
50. A few cases have reported tardive dyskinesia occurs as a result of administering 
the drug for less than three months. Roth & Appelbaum, supra note 12, at 186; M. 
LADER, supra note 1, at 61. It has also been observed that the period of greatest risk for 
tardive dyskinesia to develop may be from six to eight years of exposure to antipsychotic 
medication, while the risk is not increased if the exposure is longer than eight years. 
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founded by the fact the symptoms may become apparent only 
after a reduction in dose or from a discontinuation of the drug,'H 
because the antipsychotic drugs which produce dyskinesia can 
also mask its symptoms.'i2 Secondly, the factors predisposing a 
patient to tardive dyskinesia are not completely known, making 
it difficult to predict who will be a victim. Advancing age and 
being female are the only risk factors consistently associated 
with an increased probability of developing this syndrome.1i3 Fi-
Branchey & Branchey, Patterns of Psychotropic Drug Use and Tardive Dyskinesia, 4 J. 
CLINICAL PSYCHOPHARMACOLOGY 41 (1984); Kane & Smith, supra note 48, at 476. If the 
maximum risk for the development of tardive dyskinesia does occur as a result of rela-
tively short exposure to antipsychotic drugs, the statistical association between duration 
of exposure and this condition may become blurred when the patient population being 
studied consists of patients who have received antipsychotic treatment for prolonged pe-
riods. Branchey & Branchey, supra, at 44. 
51. M. LADER, supra note I, at 61. The term "covert dyskinesia" refers to this form 
of tardive dyskinesia. The prevalence of patients who develop dyakinesia upon discontin-
uation of the drug has been estimated to be 5% -40%. Many of these cases turn out to be 
"withdrawal dyskinesia," which is self-limited and usually disappears within 6 weeks. 
Similar to the prevailing view for the explanation of tardive dyskinesia, (see supra note 
47), withdrawal dyskinesia is thought to be the result of temporary hyperactive 
dopamineric activity when the dopamine-blocking antipsychotic drugs are discontinued. 
When the dyskinesia persists beyond six weeks, it is a strong indication that tardive 
dyskinesia was previously suppressed by drugs ("covert dyskinesia"). Gardos, Cole & 
Tarsy, Withdrawal Syndromes Associated with Antipsychotic Drugs, 135 AM. J. PSYCHI-
ATRY 1321, 1322 (1978); Gardos & Cole, supra note 42, at 788. Chronically institutional-
ized elderly patients with prolonged exposure to antipsychotic drugs are most likely to 
have developed irreversible covert dyskinesia, whereas those patients receiving drug 
treatment for a relatively shorter time are more likely to develop reversible covert dys-
kinesia. Id. 
52. Munetz, Roth & Comes, supra note 47, at 77; PSYCHIATRIC DRUGS, supra note I, 
at 17. Consequently, the symptoms may be obscured until the course of tardive dyskine-
sia is far advanced. Id. 
53. Callaway & Paull, supra note 7, at 791; Branchey & Branchey, supra note 50, at 
44; APA, supra note 29, at 1164. Factors such as a decreased neuronal plasticity or age-
related changes in drug metabolism, which leads to higher drug blood levels, may con-
tribute to the existence of increased prevalence rates of tardive dsykinesia in older pa-
tients. Kane & Smith, supra note 48, at 476. Female patients particularly those over 50 
years of age, have been found to be significantly more vulnerable than male patients to 
this side effect. Yassa, Ananth, Cordozo & Ally, supra note 47, at 393. It has been found 
that the greater the severity of tardive dyskinesia, the greater the ratio of female preva-
lence to male prevalence. Kane & Smith, supra, at 476. One possible explanation for this 
gender difference may be related to hormones. Seeman, Interaction of Sex, Age, and 
Neuroleptic Dose, 24 COMPREHENSIVE PSYCHIATRY 125, 127 (1983); Kane & Smith, supra, 
at 477. It has been suggested that estrogen induces a relative immunity to ex-
trapyramidal side effects because estrogen, known to modulate the sensitivity of 
dopamine receptors, appears to inhibit dopamine activity. This is supported by the find-
ing that women in their 20's and 30's appear to require lower doses of anti psychotics 
when estrogen levels are high, and higher doses in their 40's when estrogen levels begin 
to fall. Since antipsychotic medication decreases dopamine activity, lower doses are suffi-
cient because high levels of estrogen already present in the body act to create a similar 
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nally, although the average prevalenceli4 of this condition has 
been clearly established to be at least 20 % in chronic drug 
treated patients,1i1i the reported incidence rates, which are just 
becoming available, are widely variable.1i6 Furthermore, research 
suggesting that the incidence is increasing has caused considera-
ble debate.1I7 However, despite these controversies and the psy-
effect. Thus, increasing antipsychotic doses sufficiently to interfere with the pituitary-
gonadal hormonal system which inhibits estrogen secretion, may be counterproductive in 
controlling psychotic symptoms in premenopausal women. Seeman, supra, at 127, 128. 
Estrogen also accomodates the dopamine-acetylcholine balance lessening the occurrence 
of supersensitivity of remaining dopamine causing tardive dyskinesia. [d. at 127. There-
fore, womens' higher risk of developing tardive dyskinesia than men at an older age may 
be the result of increased supersensitivity due to postmenopausal estrogen withdrawal. 
[d. See supra note 47 regarding supersensitivity and the pharmacological basis for 
tardive dyskinesia. 
54. Prevalence rates express the proportion of patients with tardive dyskinesia at a 
particular time in a treatment facility. Gardos & Cole, supra note 42, at 776. 
55. [d. at 473; Branchey & Branchey, supra note 50, at 41; Seeman, supra note 53, 
at 125; Yassa, Ananth, Cordozo & Ally, supra note 47, at 393; Jeste and Wyatt, supra 
note 44, at 803. Although the reported prevalence of tardive dyskinesia has varied from 
.05% to more than 56%, this discrepancy in prevalence can be attributable to the follow-
ing: arbitrary definitions of tardive dyskinesia, questionable reliability of rating scales, 
and scientifically inappropriate generalizability (study populations consisting of a large 
number of elderly hospitalized patients may confound the results by not being represen-
tative of the hospital patients receiving antipsychotics). Gardos & Cole, supra note 42, at 
776. The average prevalence rate, however, should balance out these methodological 
problems, giving a valid percentage. 
56. Brooks, supra note 2, at 186; Kane, Rifkin, Woerner, Reardon, Sarantakos, 
Schiebel & Ramos-Lorenzi, Low-Dose Neuroleptic Treatment of Outpatient 
Schizophrenics, 40 ARCH. GEN. PSYCHIATRY 893 (1983) [hereinafter cited as Low-Dose]. 
Incidence (as distinct from prevalence) refers to the number of new cases emerging in a 
well-defined population during a given time period. Gardos & Cole, supra note 42, at 
776. It has been suggested there is a 12% incidence rate of tardive dyskinesia after four 
years of cummulative antipsychotic drug exposure. Low Dose, supra, at 893. Another 
study found the incidence rate to be approximately 4%-5% following one year of drug 
treatment. If the risk remains the same during each subsequent year, the incidence may 
be as high as 20% -25% over a five year period. Gardos & Cole, supra, at 776,777. Other 
reported figures have ranged from 3% to more than 50%. M. LADER, supra note 1, at 61. 
57. Comment, Madness & Medicine, supra note 29, at 533 n.163. The reported fre-
quency of tardive dyskinesia depends on how carefully one looks for the complication, 
thus as researchers become more sophisticated in diagnosing tardive dyskinesia, they are 
able to detect it in an increasing number of patients. However, the American Psychiatric 
Association has asserted that the currently heightened awareness of tardive dyskinesia 
with increased sensitivity to minor degrees of abnormal movements may be leading to 
diagnosis based on abnormal movements unrelated to antipsychotic drug use. These ab-
normalities include minor movements that may be indistinguishable from habit spasms 
or other tics of unknown cause, psychotic mannerisms, or even normal movements asso-
ciated with ill-fitting dentures. Furthermore, the geriatric population and schizophrenic 
population apparently have a greater incidence of naturally occuring movement abnor-
malities. APA, supra note 29, at 1164. To the contrary, see Munetz, Roth & Cornes, 
supra note 47, at 82 addressing this "myth," where only two of the 46 diagnoses of 
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chiatric research indicating that only a relatively small number 
of patients may actually experience tardive dyskinesia, for those 
that do, all of this seems irrelevant.CiB From a legal point of view, 
however, documented evidence of a high incidence of tardive 
dyskinesia is not necessary to warrant protective action. The 
possibility that a significant number of chronic mentally ill indi-
viduals may unnecessarily develop a permanent neurological dis-
order is sufficient.Ci9 
Other adverse reactions which have been associated with 
the use of antipsychotic drugs, are jaundice,60 potentially fatal 
blood dyscrasias,61 blindness,62 and cardiac arrhythmias.63 Ex-
tardive dyskinesia studied were at all in question following a careful review of each case. 
Also the standard use of either the Abnormal Involuntary Movement Scale (AIMS) de-
veloped at the National Institute of Mental Health, or the Dyskinesia Rating Scale in 
most of the recent studies appears to undercut the APA's assertions. Jeste & Wyatt, 
supra note 44, at 804. 
58. Furthermore, although not all those afflicted with tardive dyskinesia suffer the 
more severe abnormal' muscular movements, even mild dyskinesia manifested by minor 
facial tics can be extremely distressful for the individual, and he or she consequently 
may become withdrawn. Likewise the facial movements can make a person highly unat-
tractive and thus limit employment opportunities, as well as social adjustment. Gardos & 
Cole, supra note 42, at 777; PSYCHIATRIC DRUGS, supra note 1, at 16. It has been esti-
mated that of the total 20% of patients with tardive dyskinesia (see supra note 55 and 
accompanying text) less than 10% have severe abnormal movements while 25%-35% 
show moderately severe movements. Munetz, Roth & Cornes, supra note 47, at 77. See 
APA, supra note 29 at 1164 (Table 2) for prevalence of tardive dyskinesia, in various 
degrees of severity, among chronic schizophrenic inpatients and outpatients treated with 
these drugs. 
59. See supra note 29. 
60. PSYCHIATRIC DRUGS, supra note 1, at 16. The incidence of jaundice is relatively 
uncommon and is the result of a hypersensitivity reaction, most likely to occur between 
the second and fourth weeks of therapy. Resembling infectious hepatitis, it is usually 
reversible on withdrawal from the medication, although instances of chronic jaundice 
have been reported. 38 PHYSICIANS DESK REFERENCE 1897 (1984) (package insert for 
Thorazine); M. LADER, supra note 1, at 62. 
61. The most significant blood dyscrasia is agranulocytosis, a condition in which 
bone marrow production of white blood cells is reduced or stopped leading to an in-
creased susceptibility to infection. This rare toxic effect occurs in one out of 3,000 pa-
tients treated with chlorpromazine (Thorazine) and 30% of these cases are fatal (one 
chance in 10,000 a patient will die from treatment). Dubose, supra note 29, at 537 n.180. 
See id. and package insert for Thorazine in 38 PHYSICIANS DESK REFERENCE 1897 (1984) 
for a discussion of other blood dyscrasias. 
62. Retinitis, or retinal degeneration which may result in blindness, is caused by one 
drug, thioridazine (Mellaril) if dosages over the manufacturer's recommendation are be-
ing administered. PSYCHIATRIC DRUGS, supra note 1, at 16; M. LADER, supra note 1, at 62. 
63. PSYCHIATRIC DRUGS, supra note 1, at 16. Persons treated with phenothiazines 
have been shown to have nonspecific abnormalities in their electrocardiograms, particu-
larly those receiving thioridazine (Mellaril). Brown & Kocsis, Sudden Death and Anti-
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tremely rare cases of sudden death have been reported from 
such arrhythmias.64 
In addition to these purely physical side effects, the psycho-
logical effects can be extremely anti therapeutic, particularly in 
view of the purported benefit that antipsychotic drugs serve by 
allowing the chronic mentally ill to be integrated into society. 
Apart from the emotional distress arising from experiencing any 
of the physical side effects aforementioned, these drugs directly 
effect an individuals cognition, emotion, and motivation. 6C1 Re-
search has indicated these drugs generate a "cognitive dampen-
ing," impairing a patient's ability to remember, reason, or func-
tion effectively in any complex learning situation, whether it be 
psychotic Drugs, 35 Hosp. & COMMUNITY PSYCHIATRY 486, 488 (1984). These abnormali-
ties can be the forerunner of fatal cardiac tachyarrhythmias (excessively rapid heart 
beat). [d. at 487; Comment, Madness & Medicine, supra note 29, at 537 n.179. 
64. Sudden death is a phenomenon which can occur in previously healthy persons. 
There is a substantial incidence of sudden death in the general population, more than 
400,000 cases per year, representing one such death every minute. Although most victims 
are men who have coronary atherosclerosis, 25% have no recognizable cardiac disease. 
Brown & Kocsis, supra note 63, at 486, 487. Ventricular tachycardia or fibrillation (fine 
rapid uncoordinated twitching of individual muscular fibers, replacing the normal con-
traction of the ventricular muscle) accounts for more than 75% of such deaths. It is 
assumed that all persons who die suddenly from ventricular tachycardia have previously 
had arrhythmias, but not all patients with arrhythmias die of ventricular tachycardia. [d. 
at 487. Consequently, case reports of sudden death precipitated by antipsychotic induced 
arrhythamias are controversial, as well as inconclusive, in that this area is limited by 
retrospective data gathering, small sample size due to its rarity, and often sparse histori-
cal and laboratory data. [d. at 486. Furthermore, given the substantial incidence of sud-
den death in the general population, a certain proportion of medicated patients can be 
expected to coincidentally die suddenly even if no harmful effects are exerted by antip-
sychotics. However, on the basis of what is known about risk factors for ventricular 
tachycardia in the general population and the action of phenothiazines in producing ar-
rhythmia, the psychiatric benefits must be weighed against cardiac risks in persons indi-
cating any type of predisposing cardiovascular pathology. [d. at 490. 
Phenothiazines have also been shown to depress the cough and the gag reflexes. Ab-
sence of the gag reflex has been reported in 40.3% of psychiatric patients. Zugibe, Sud-
den Death Related to the Use of Psychotropic Drugs, in LEGAL MEDICINE 1980 75, 76 (C. 
Wecht ed. 1980). This sudden death by asphyxia has been implicated when patients 
show sudden respiratory difficulty followed by collapse shortly after eating (autopsies 
finding food in the larynx or trachea). Brown & Kocsis, supra, at 488. However, a direct 
relationship to the drugs has not been established, attributed largely to the fact individ-
uals receiving anti psychotics do not choke on food anymore frequently than do nonp-
sychiatric individuals. Zugibe, supra, at 78. See generally Brown & Kocsis, and Zugibe 
supra for further discussion of cardiovascular side effects and respiratory complications 
arising from the use of the drugs which have been associated with sudden death. 
65. Comment, Madness & Medicine, supra note 29, at 534; Brooks, supra note 2, at 
184. 
17
Goode: Regulating Antipsychotic Drugs
Published by GGU Law Digital Commons, 1985
348 GOLDEN GATE UNIVERSITY LAW REVIEW [Vol. 15:331 
social or interpersona1.66 Thus, if a goal of rehabilitation is to 
replace chronic disability with self-sufficiency, antipsychotics 
have serious liabilities. Furthermore, these drugs produce list-
lessness and apathy, a characteristic "flattening" often described 
by mental patients by the term "zombiism."67 Given this reduc-
tion in motivation, it is not surprising that it has been reported 
that a majority of chronic patients who live in the community 
continue to be unproductive and are often a burden to their 
families. 68 It has also been asserted that the "flattening" effect 
of antipsychotic medications may lead to the development of su-
icidal depression precipitated by feelings of emptiness, worth-
lessness, and loss of self.69 Consequently, individuals who receive 
these drugs not only risk a wide variety of physical side effects, 
but must also relinquish any true sense of self-determination, 
66. PSYCHIATRIC DRUGS, supra note I, at 21; Comment, Madness & Medicine, supra 
note 29, at 534. This raises the question of effectiveness of use of these drugs in conjunc-
tion with psychotherapy in that various kinds of interpersonal learning are involved; the 
patient is expected to learn from the therapist about how to view, react, or cope more 
effectively with his environment. PSYCHIATRIC DRUGS, supra note I, at 21. 
67. Brooks, supra note 2, at 184. This drug effect is the consequence of the suppres-
sion of dopamine activity in the limbic system which is involved in the regulation of 
emotion and motivation. It is this same effect which is responsible for the drugs' ability 
to reduce disordered thought and alleviation of psychotic anxiety. Comment, Madness & 
Medicine, supra note 29, at 534. The following account of this "zombiism" by a diag-
nosed schizophrenic illustrates the extent to which a patient may be overwhelmed by 
apathy and emptiness: 
What the drug is supposed to do is keep away hallucinations. 
What I think it does is just fog up your mind so badly you 
don't notice the hallucinations or much else. 
On Thorazine everything's a bore. Not a bore, exactly. Bore-
dom implies impatience. You can read comic books and 
"Reader's Digest" forever. You can tolerate talking to jerks 
forever. Babble, babble, babble. The weather is dull, the flow-
ers are dull, nothing's very impressive. Muzak, Bach, Beatles, 
Lolly and the Yum-Yums, Rolling Stones. It doesn't make any 
difference. 
M. VONNEGUT, THE EDEN EXPRESS 252-53 (1975) reprinted in Psychiatric Drugs, supra 
note I, at 19, 20. 
68. Crane, supra note 28, at 125. 
69. Comment, Madness & Medicine, supra note 29, at 538. Depression may also be 
a secondary reaction to the physical side effects, particularly those of the akinetic type 
(see supra notes 42-43 and accompanying text). Brooks, supra note 2, at 185. However, 
drug induced suicidal depression is not without controversy by virtue that irrespective of 
medication, schizophrenic patients often have mood swings, and suicide is at least 50 
times more common among schizophrenics than among the general population. M. 
LADER, supra note I, at 62. 
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emotion, and enthusiasm for life. 
B. The Use Of Antipsychotic Drugs In The Private Sector 
It should be evident at this point that the use of antipsy-
chotic drugs in the treatment of the chronic mentally ill poses 
many delicate and perplexing questions both for the patient and 
the physician. Even in the realm of sound clinical practice when 
a decision is made that continued medication is necessary, a pa-
tient must, nonetheless, be subjected to the inherent risks of 
debilitating side effects. Although the medical benefits of these 
drugs are disputable when viewing chronic patients as a whole,70 
the decision to continue drug therapy in an individual case may 
be one of valid professional medical judgment and in such in-
stances, legal intrusions in the practice of medicine would be in-
appropriate.71 Thus it is important to draw the distinction be-
tween the difficult question of the usefulness of antipsychotic 
drugs in the treatment of chronic disorders in general, and the 
prescription of these drugs to control unwanted behavior solely 
for the benefit of nursing staff or relatives, without substantial 
benefit to the patient. It seems clear that in the latter situation, 
chronic patients are exposed to the hazards of these drugs with-
out justification. 
This problem is not limited to the practice of psychiatry in 
the public sector.72 Negligent and even abusive use of this medi-
cation in board and care homes and in nursing homes necessi-
tates examination of the heretofore sacrosanct boundary be-
tween the public and private practice of medicine to afford all 
patients protection from such medication practices. Although 
the following two Sections will examine the use of antipsychotic 
drugs in these two specific areas, it is important to keep in mind 
70. See supra note 29. 
71. The decision that long-term drug therapy is required is dictated by diagnosis, 
and as the U.S. Supreme Court has stated, "[tlhe subtleties and nuances of psychiatric 
diagnosis render certainties virtually beyond reach . . . . Psychiatric diagnosis . . . is to 
a large extent based on medical 'impressions' drawn from subjective analysis and filtered 
through the experience of the diagnostician. This process often makes it very difficult for 
the expert physician to offer definite conclusions." Addington v. Texas, 441 U.S. 418, 430 
(1979). Accordingly, legal intervention is limited to cases of medical negligence. See infra 
note 153 where the court has determined that long-term administration of these drugs 
amounted to malpractice. 
72. See supra note 10. 
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that the potential for misuse of these drugs exists in all other 
areas of private medicine as well. 
1. Nursing Homes 
Approximately five percent of people age 65 and older in 
the United States are confined to nursing homes.73 The potential 
for abuse of antipsychotic drugs is tremendous in the nursing 
home setting where long-term residents are often vulnerable, 
frail, alone and utterly dependent on those who care for them. 
In fact, it has been established that large numbers of elderly pa-
tients are kept in a drugged state to keep them manageable.'" 
The ramifications of antipsychotic drug use as a way to con-
trol behavior rather than for specific psychiatric treatment are 
extreme in this age population. Not only can these drugs acceler-
ate the deterioration of general health in ambulatory patients by 
inducing muscular atrophy,711 but their detrimental side effects 
are far more likely to occur in geriatric patients.76 Furthermore, 
73. Dyer, Oles & Davis, Geriatrics & Gerontology-The Role of the Pharmacist in a 
Geriatric Nursing Home: A Literature Review, 18 DRUG INTELLIGENCE & CLINICAL PHAR-
MACY 428 (P. Lamy ed. 1984). In California 1,170 nursing homes care for 105,000 people 
each day. Task Force Blasts Abuse of Elderly in Nursing Homes, L.A. Daily J., August 
18, 1983, at 1 col. 4 [hereinafter cited as Abuse of Elderly). 
74. J. ROBITSCHER, THE POWERS OF PSYCHIATRY 359 (1980). An investigation of nurs-
ing homes in Los Angeles and San Francisco revealed that patients were kept in drugged 
conditions as a way of lessening the burden of care on the staffs. Abuse of Elderly, supra 
at 1, col. 4. A study addressing antipsychotic drug use in 173 Tennessee nursing homes 
found epidemiologic evidence of abuse in that 43% of the patients were prescribed anti-
psychotic medication. Ray, Federspiel & Schaffner, A Study of Antipsychotic Drug Use 
in Nursing Homes: Epidemiologic Evidence Suggesting Misuse, 70 AM. J. PUBLIC 
HEALTH 485, 490 (1980). The Nader Task Force on Nursing Homes charged tranquilizers 
were given mostly for staff convenience. F. Moss & V. HALAMANDARIS, Too OLD Too SICK 
Too BAD: NURSING HOMES IN AMERICA 45 (1977). See id. at 45-48 for various testimonies 
from nursing home personnel before a U.S. Senate subcommittee on Long-term Care 
(1971) substantiating that in many instances the sole purpose of these drugs was that of 
quieting patients. 
75. PSYCHIATRIC DRUGS, supra note 1, at 20. 
76. With increasing age there is a decrease in the rate of drug metabolism, which 
may account for the relatively high evidence of adverse drug reactions in older patients. 
Drug Interactions and Reactions Update (P. D'Arcy ed.) 16 DRUG INTELLIGENCE & 
CLINICAL PHARMACY 925 (1982). The potentiation of drug effects with age are poorly un-
derstood. Although most elderly patients require dosage reductions of antipsychotic 
drugs due to the declining efficiency of the liver and kidneys, the effect of changes in 
drug protein binding in the blood, changes in the distribution and quantity of body 
water and fat with age, and changes at receptor sites in the brain are areas of specula-
tion. Also the effects of nutritional deficiencies and diseased organ systems on pharmaco-
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since geriatric patients frequently suffer from an array of physi-
cal conditions, the average nursing home resident receives four 
to seven prescriptions daily," which increases the likelihood of 
adverse drug interactions.78 As a result of this polypharmacy, 
many patients suffer from adverse and paradoxical drug reac-
tions that are never diagnosed because the idiosyncratic behav-
ior exhibited by the patient is seen as part of the aging or dis-
ease process, and thus is unrecognized as a drug side effect.79 
The problem of inadequate control of antipsychotic drug 
use and overmedication is perpetuated by inadequate physician 
contact,80 the overuse of prn (pro re nata which means as 
logic actions are yet to be ascertained. Dyer, OIes & Davis, supra note 73, at 430. See 
supra note 53 regarding the aging factor and tardive dyskinesia. Phenothiazine-induced 
Parkinsonism (akinesia) also occurs more frequently among the aged. M. LADER, supra 
note 1, at 65; F. Moss & V. HALAMANDARIS, supra note 74, at 182. 
77. Certain patients even receive up to 18 or more daily medications. Dyer, OIes & 
Davis, supra note 73, at 428; J. ROBITSCHER. supra note 74, at 359. 
78. The chances for serious drug interactions, adverse effects on disease states, and 
adverse drug reactions rise proportionately as the number of prescriptions increases. The 
incidence of adverse drug reactions also increases with the age of the patient. Dyer, OIes 
& Davis, supra note 73, at 429. It has been reported that greater than 50 percent of the 
people in nursing homes are receiving drugs which potentially interact and are conse-
quently quite dangerous. F. Moss & V. HALAMANDARIS, supra note 74, at 52. See Salzman 
& Hoffman, Clinical Interaction Between Psychotropic and Other Drugs, 34 HOSPITAL & 
COMMUNITY PSYCHIATRY 897, 897-99 (1983) for a listing of drug interactions with antip-
sychotics, indicating those that are of clinical significance and may interfere with treat-
ment or even be life-threatening. 
79. Delineating what behavior is actually a manifestation of the aging process or the 
progression of a physical illness and what is the result of a drug side effect poses a very 
real obstacle in determining the extent the medication regimen is harmful to the patient. 
The use of multiple drugs often stems from the fact that complaints of elderly patients 
are difficult to diagnose and certain diagnostic tests may not be readily available in a 
nursing home. Also, physicians may be hesitant to order such tests that may expose older 
patients to physical risks and increase the cost of care. Consequently, physicians fre-
quently prescribe medications which reduce the pain or intensity of the symptoms in-
stead of determining its underlying source. These medications may accumulate in the 
body so that it is difficult to differentiate which are beneficial and which are contributing 
to the patients problem. Dyer, OIes & Davis, supra note 73, at 428-29. 
80. Id. at 429. The underlying reasons why private physicians all too frequently 
maintain only minimal contact with nursing home patients leading to an apparent abdi-
cation of their responsibilities in caring for such patients may involve a variety of diffi-
cult factors. One possible factor may be what one United States Senator has labeled the 
"Marcus Welby Syndrome." F. Moss & V. HALAMANDARIS, supra note 74, at 178. This 
syndrome is perpetuated because the primary emphasis of medical education in the 
United States is acute illness. Therefore, many physicians have not received any special-
ized training in the area of geriatric medicine, making the acute hospital the focus of the 
medical profession. Besides this insufficient training and understanding in geriatrics, 
physicians may have a personal aversion to having to deal with large numbers of chroni-
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needed) prescriptions,81 and rapid staff turnover particularly 
common in the nursing home industry.82 Infrequent physician 
contact results in patient care being delegated to nursing staff,83 
which may in turn lead to a continuation of medications beyond 
their clinical usefulness,84 confusion about dosage levels, and 
telephone communication errors.811 Because nursing staff turno-
ver is higher, patients may repeatedly be exposed to undesirable 
cally ill patients, growing out of ego, pride and the desire to "cure" patients. As with any 
individual, the physician must maintain self-esteem if he/she is to live and work effec-
tively. Thus, where the physician's self-evaluation is grounded in being capable of elimi-
nating pain and restoring health, self-esteem can easily suffer when no clear improve-
ment in the patient can be seen as a result of his/her efforts. No matter how false this 
rationalization, with its resulting neglect of the patient, many physicians avoid nursing 
home patients because they feel they are unable to heal them. [d. at 177, 178. Other 
disincentives range from inconvenience from traveling to nursing homes isolated from 
hospitals, inadequate compensation and uncertainty of payments in the administration 
of Medicare and Medicaid, to their own frustration at the lack of back-up support avail-
able as a result of untrained nursing home personnel. Physicians may also unconsciously 
wish to avoid the depressing and unpleasant atmosphere in a nursing home, particularly 
when physicians themselves are approaching nursing home age. See id. at 172-78. 
81. The extensive drug use among elderly patients is complicated by the number of 
drugs prescribed on a prn basis. See supra note 10. It has been estimated that prn medi-
cation use ranges from 3.2 orders to 4.1 orders per patient. Dyer, Dies & Davis, supra 
note 73, at 430. Antipsychotic drugs often are given on a prn basis. One study revealed 
that 53% of all psychoactive drugs were prescribed on a prn basis. Thus arises the ability 
of nursing staff to control patients who are inconvenient for the staff. [d. 
82. Staff turnover is the unavoidable consequence of a high degree of job dissatisfac-
tion. For any number of nursing home staff, working in a setting in which one is rou-
tinely both witness and party to a lack of attention to the patient's human needs can 
become extremely unsettling over a prolonged period of time. Undesirable working con-
ditions as well as unattractive economic compensation often makes labor-force stability 
under these conditions an impossibility. Rango, Sounding Boards: Nursing Home Care 
in The United States, 307 NEW ENG. J. MED. 883, 887 (1982). 
83. This problem is exacerbated by financial constraints which can limit staff levels 
to the minimum legal requirement. Thus the trained professional staff (Le., registered 
nurses and consulting pharmacists) become heavily burdened with administrative duties. 
Consequently, the least trained personnel may become responsible for patient care. Fur-
thermore, the effect of rapid staff turnover implicates that many of these lower level 
nursing staff personnel are relatively new in their jobs and to a lesser extent able to 
handle medication problems. Dyer, Dies & Davis, supra note 73, at 429. 
84. [d. at 430. This can often be attributed to the fact that prn drugs are not used 
routinely in many cases, so that these orders may continue unnoticed indefinitely. [d. 
Even when antipsychotic drugs have been prescribed for legitimate purposes (i.e., schizo-
phrenia) the lack of review of patient medication needs because of such prn orders may 
result in overdosage. Since the schizophrenic process is not static, a patient may be func-
tioning at a level which requires less medication. PSYCHIATRIC DRUGS. supra note 1, at 25. 
85. The opportunity for such an occurrence cannot be underestimated when most 
medications are prescribed over the telephone. One nursing home administrator testified 
before the United States Senate Subcommittee on Long-term Care that if it weren't for 
Alexander Graham Bell, there would be no medicine practiced in the United States long 
term homes. F. Moss & V. HALAMANDARIS. supra note 74, at 182. 
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side effects.86 
The Federal government has attempted for almost twenty 
years to address some of these problems.87 Concern over drug 
interactions and medication errors instigated the Department of 
Health, Education and Welfare (DHEW) to allocate large sums 
of money toward training programs for pharmacists who could 
perform clinically-oriented services such as drug therapy moni-
toring.88 In 1974, when DHEW promulgated regulations imple-
menting the Social Security Act of 1972, the pharmacist's posi-
tion in skilled nursing facilities changed from one of an 
administrator of drug distribution systems to the individual pri-
marily responsible for promoting the rational clinical use of 
drugs.89 Although the states retain the right to expand the role 
of the consultant pharmacist, most have not.90 Furthermore, in 
all cases, the physician retains the privilege to reject the phar-
macist's recommendations,91 since the pharmacist has no author-
ity to alter a patient's drug regimen.92 Apparently, however, 
given the continuing abuse of drugs, particularly antipsychot-
86. Again this can often be attributed to the widespread use of prn medications 
contributing to problems of drug reactions and interactions (e.g., when a previously pre-
scribed prn medication produces an undersirable interaction with a recently prescribed 
drug). Dyer, Oles & Davis, supra note 73, at 430. 
87. Id. at 429. 
88.Id. 
89. In addition to the pharmacist's traditional responsibilities of drug procurement, 
distribution, and control, the regulations require the pharmacist to monitor each pa-
tient's drug therapy at least monthly. [d. 
90. Id. One state that has extended beyond the federal requirement that a pharma-
cist review drug therapy of all patients monthly is North Carolina. Regulations for the 
licensure of nursing homes in that state specify that all new orders should be reviewed 
against existing ones to prevent drug interactions. The pharmacist's monthly check must 
also involve an examination of the patient's medical record, including physicians' orders 
and progress notes as well as any nurses notes, results of laboratory procedures, dis-
charge summaries, medical histories, and physical examination reports. [d. While such a 
drug monitoring system is admirable, the fact that North Carolina's standards are built-
in to state licensing requirements presents problems associated with enforcement. At-
tempts at quality assurance by way of licensing has not proved to be an effective tool, 
because such standards aggravate local problems of access by making needed services 
even scarcer in a given area. Rango, supra note 82, at 887; California Assembly Perma-
nent Subcommittee on Mental Health and Developmental Disabilities, Improving Cali-
fornia's Mental Health System: Policy Findings and Recommendations 46, 47 (1978) 
[hereinafter cited as Policy Findings]. 
91. Dyer, DIes & Davis, supra note 73, at 429. Studies addressing physician accept-
ance of pharmacist's recommendations have found at least a 60 percent acceptance. Id. 
at 432. 
92.Id. 
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ics,93 this expanded role of the pharmacist as consultant has not 
proven sufficient. 
In addition to the large number of patients who may be re-
ceiving antipsychotic drugs solely for management purposes, the 
chronic mentally ill may be subjected to negligent or excessive 
use of this medication simply because nursing homes have tradi-
tionally been ill-prepared to handle such patients.9• Nonetheless, 
nursing homes suddenly became new depositories for the chronic 
patient as a result of deinstitutionalization. California is a per-
fect example of a state's ambitious program to empty state hos-
pitals and place patients in nursing homes and other small com-
munity based programs. There were 12,000 aged in California 
state hospitals in 1959 and by 1974 only 578 remained institu-
tionalized.911 An unfortunate consequence of moving elderly pa-
tients from state hospitals, is that staff at nursing homes merely 
provide housing and supervision rather than focusing on rehabil-
itation.96 In such an environment, there is a substantial likeli-
hood that the sole form of treatment would be drug therapy. 
The serious psychological problems, with serious interpersonal 
relationship problems may very well be far more than most un-
trained nursing staff personnel can manage, especially when they 
are expected to concurrently manage severe physical disabilities 
in the same patients. Thus, antipsychotic medication may be 
negligently administered in excessive amounts as a way for the 
staff to handle these patients to the best of their ability given 
their lack of psychiatric training. 
Because these wide variety of factors contributing to abu-
sive or negligent use of anti psychotics in nursing homes are in-
terwoven, many of them could be controlled by the physician. If 
there were more physician contact with patients, the need for 
such an abundance of prn prescribing should diminish and 
lessen the potential for overdosing and drug interactions. How-
93. See supra note 74. 
94. F. Moss & v. HALAMANDARIS, supra note 74, at 104. 
95. Id. See id. at 105 (Table 6-1) demonstrating this national trend in each individ-
ual state. A major impetus for the massive transfer from state hospital into the commu-
nity was the desire to preserve state dollars and replace them with federal dollars. See 
supra note 6. 
96. F. Moss & V. HALAMANDARIS, supra note 74, at 113. Any individual showing 
some degree of mental impairment may quickly receive the label of "senility" which may 
connote to staff that the patient is "hopeless" and can be ignored. Id. 
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ever, too many private physicians treating nursing home pa-
tients continue to avoid the nursing homes, making greater phy-
SICIan contact for many patients an impracticality. The 
monitoring of prescriptions via legislatively imposed regulations 
would serve to alleviate this misuse of antipsychotic drugs con-
sequent to insufficient physician contact. 
2. Board And Care Homes 
A large number of persons receiving antipsychotic drugs in 
board and care homes97 are also in the private sector.98 Many of 
these facilities house large numbers of psychiatric patients in-
cluding both the de institutionalized and new generations of 
chronically mentally ill.99 Unlike some nursing homes, board and 
care homes are for the most part adequate in the sense there is 
no life-threatening neglect or other gross abuses. loo Accordingly, 
any inappropriate use of antipsychotic drugs in this environ-
ment most likely has its origin in failing to carefully monitor the 
individual for adverse reactions or the continuing necessity of 
97. In California, the term "board and care homes" is used to describe a variety of 
unlocked facilities providing a shared room, three meals a day, dispensing of medication, 
and minimal staff supervision for residents ranging from one to more than one hundred 
in number. Lamb, supra note 6, at 903. 
98. It is important to distinguish, for purposes of this discussion, those residents 
who are under a private physician's care as opposed to receiving outpatient services from 
state or county facilities. Outpatient services provide short· term or sustained therapeutic 
intervention for individuals experiencing acute or ongoing psychiatric distress. Relevant 
to this discussion, it is mandatory that antipsychotic medication prescribed and dis-
pensed through state hospital outpatient services must also be accompanied by evalua-
tion of side effects and results of medication. CAL. ADMIN. CODE tit. 9, R. 543 (1984). 
Residents receiving care through outpatient services from county physicians are afforded 
some form of protection by virtue of the medication monitoring system. See supra note 
24. Thus this discussion of board and care homes is focused on the potential problems of 
antipsychotic drug usage in relation to residents under the supervision of private physi-
cians. Board and care homes are required by state law to provide a physician, while 
county regulations may require an additional psychiatrist, or a physician who is also a 
psychiatrist (e.g., San Francisco County). Telephone interview with John Riggs, Director 
of Board and Care Residences, San Francisco (Nov. 14, 1984). 
99. Lamb, supra note 6, at 903. 
100. [d. While many enter in the nursing home industry for profit, operators of 
board and care facilities are most likely operating such a facility out of genuine concern 
for their residents. Those housing the mentally ill only receive a flat rate of $476.00 per 
month for each resident, a clear indication that operators, many who have opened their 
own homes to these individuals, are not managing a board and care home for the money. 
[d. Since there is a great deal of variability in these facilities, any attempts to generalize 
would clearly be erroneous. Rather this discussion is merely bringing to attention the 
possibility for negligent use of these drugs given the circumstances. 
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drug therapy.lol 
By the very nature of a board and care home setting, in that 
it is only a 24-hour a day nonmedical care and supervision shel-
ter, medications may not be adequately supervised and opera-
tors of board and care homes may lack training in observing an 
individual's response to antipsychotic medication. lo2 Often the 
patient either has to become a behavior problem or develop a 
very serious, obvious side effect before the board and care opera-
tor can detect that the medication needs to be altered. lo3 Thus, 
the prescribing physican's attentiveness is the only reliable 
means for the monitoring of medication. 
The extent to which this responsibility is carried out by pri-
vate physicians has not been established. Testimony before the 
California Assembly Subcommittee on Mental Health and De-
velopmental Disabilities revealed that it was common practice 
for medication to be reviewed only once a month in board and 
101. However, these drugs may also be prescribed to solve management problems 
within the board and care homes. These drugs can often take on such a function as a 
result of physicians, family members, and board and care staff fearing potential acts of 
violence, while failing to distinguish between manifestations of illness and the individ-
ual's reaction to frustrations arising from the deprivation of the environment in which he 
is forced to live (for many, the only alternative would be homelessness) or frustrations 
from unpleasant and uncontrollable side effects (see supra notes 31-69 and accompany-
ing text). Crane, supra note 28, at 125; Lamb, supra note 6, at 903. 
102. PSYCHIATRIC DRUGS, supra note I, at 18. Although this speculation is one di-
rectly related to the quality of staff, the chronic mentally ill in board and care homes 
may be experienc,ing a drain in resources and personnel as a result of the significantly 
higher funding available for similar resources for the developmentally disabled. In Cali-
fornia, the 1984 rate paid to operators of homes for the developmentally disabled varied 
from a minimum of $525/month for easily manageable residents to $840/month for "in-
tensive treatment." Since there is only one flat rate of $476/month for the mentally ill, 
regardless of the severity of the problem and the need for intensive supervision and care, 
many of the better board and care operators have stopped serving the mentally ill so 
that they may take advantage of the higher rates for the developmentally disabled. 
Lamb, supra note 6, at 903. 
103. Policy Findings, supra note 90, at 54. Thus, if a person is exhibiting symptoms 
of akathisia (see supra notes 40-41 and accompanying test) which can easily be mistaken 
as anxiety or agitation, a board and care operator might not think it necessary to notify 
the home's physician. The emergence of fine abnormal movements associated with 
tardive dyskinesia (see supra notes 44-47 and accompanying text) can also go unnoticed. 
This may be extremely important because tardive dyskinesia has a better prognosis if 
recognized early in the onset of the syndrome. Gardos & Cole, supra note 42, at 779; 
Glazer, Moore, Schooler, Brenner, & Morgenstern, supra note 44, at 626; Munetz, Roth 
& Cornes, supra note 47, at 77. 
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care homes. l04 Although it is arguable whether this is sufficient 
physician contact in cases where the patient has stabilized and 
the physician is certain that the drug regimen is the most appro-
priate,I°5 newer patients need to be monitored at least bi-weekly, 
or even weekly, for adverse reactions. lOS Furthermore, the extent 
to which this medication review entails assessing whether dos-
ages can successfully be lowered or discontinued so as to mini-
mize side effectsl07 and ensure against overmedication appears 
questionable. l08 Consequently, although it would be unfair to 
generalize about the actual prescribing practices of these physi-
cians, the chronically mentally ill may, nonetheless, be put in 
the precarious position of enduring unnecessary side effects, 
with increasing risk of irreversible tardive dyskinesia, if, in fact, 
physicians fail to continuously monitor and evaluate the appro-
priateness of treatment. 
Assuming that there are chronically mentally ill who do not 
need anti psychotics or for whom these drugs are harmful rather 
than helpful, the use of long-acting injectable tranquilizers de-
serves special attention. Injectable fluphenazine, marketed 
under the brandname Prolixin Deconoate, provides for maxi-
mum control of the patient and psychotic symptoms with mini-
mum contact by the physician. l09 A single injection may be ef-
104. Policy Findings, supra note 90, at 54. 
105. This amount of contact may be viewed as insufficient from the standpoint of 
monitoring patient compliance when these drugs are in fact necessary. It has been esti-
mated that approximately one half of all oral medications prescribed are somehow dis-
carded. J. ROBITSCHER, supra note 74, at 360. Likewise, studies have revealed that ap-
proximately 50% of those given prescriptions for antipsychotic drugs stop taking them 
for one or more of the following reasons: 1) side effects, particularly sedation, 2) com-
plexity of regimen, 3) lack of social supervision, and 4) severity of illness (default rates 
have been shown to be highest in those schizophrenics who are most ill at time of dis-
charge). It has also be reported that there are a small group of patients, most of whom 
have grandiose delusions, who prefer their psychotic state to drug-induced version of 
reality. PSYCHIATRIC DRUGS, supra note I, at 18. 
106. Policy Finding, supra note 90, at 54. 
107. Low dosages of antipsychotic medication appears to have a significant advan-
tage in producing fewer early signs of tardive dyskinesia (see supra notes 44-57 and ac-
companying text). Low-Dose, supra note 56, at 896; Seeman, supra note 44, at 125; 
Pirodsky, supra note 4, at 59. Lower doses also may help alleviate akathisia (see supra 
notes 40-41 and accompanying text). APA, supra note 29, at 1164. 
108. A study of a representative sample of all board and care residents in California 
found 39% of the patients were on dosages higher than recommended for outpatient 
treatment by noted psychopharmacologist Leo Hollister. PSYCHIATRIC DRUGS, supra note 
I, at 20. 
109. Squibb Pharmaceutical Company which markets Prolixin, emphasizes in its ad-
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fective in controlling schizophrenic symptoms up to four weeks 
or longer, and in some patients the response has been found to 
last as long as six weeks.l1O Thus, this drug serves as the ulti-
mate approach in impersonal treatment, having the potential to 
deemphasize any psychiatric approach that is based on a long, 
slow development of a therapist-patient relationship. 
The use of Prolixin has been advocated as a method of cir-
cumventing dependence on untrained board and care operators 
to supervise patient compliance.ll1 However, it has the tremen-
dous disadvantage of being used to indiscriminately treat pa-
tients without emphasis on the patient as an individual. Fur-
thermore, if the patient has a strong adverse reaction to the 
injection, the patient has to suffer for several weeks because it 
takes that long to metabolize the medication.1l2 The most appar-
ent danger of the Prolixin approach, however, is that because it 
is cheap and impersonal, and does not require much investment 
of professional skills, a physician having such limited contact 
with a patient may maintain that patient on Prolixin long after 
the need for medication is over.l1S 
Antipsychotic medication plays an extremely important role 
in community based facilities such as board and care homes, for 
it may be the only form of treatment available.114 This, however, 
does not justify its continued use, without attempting to taper 
vertising campaign that the use of Prolixin saves "times, money, and people." J. ROBIT-
SCHER, supra note 74, at 362. 
110. 38 PHYSICIANS' DESK REFERENCE 1934, 1935 (1984) (package insert for Prolixin 
Decanoate). 
111. J. ROBITSCHER, supra note 74, at 360. See supra note 105 for a discussion of 
patient compliance. 
112. Whereas other antipsychotic medication only has a 24 hour half-life, a strong 
reaction can be remedied either by a reduction in dose or discontinuation of the drug. 
Telephone interview with Dr. Steve Schone, Deputy Director of Clinical Services, Cal. 
Dept. of Mental Health (Nov. 6, 1984). The side effects of depot (long-acting) 
fluphenazines may also be more severe than other antipsychotic medication. One study 
of outpatients on depot injections showed that 45% had signs of Parkinsonism (although 
they were also receiving antiparkinsonism drugs), 8% had tardive dyskinesia, and 21 % 
suffered from motor restlessness (akathisia). J. ROBITSCHER, supra note 74, at 361. 
113. J. ROBITSCHER, supra note 74, at 362. 
114. Community based treatment is effectively contradicted by Medicaid and Medi-
care provisions which only pay for hospitalization and medications. Thus, for the many 
board and care residents who are welfare recipients, if no community treatment pro-
grams are readily available, the only form of treatment which they can afford is drug 
therapy, covered by Medicaid (MediCal). Goleman, 'Snakepits,' Jails Are No Answer, 
and Lawyers Push Alternatives, L.A. Daily J., April 30, 1984, at 4, col. 3. 
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medication, when there is even a remote possibility an individ-
ual could function without it. Thus, it is important that the phy-
sician not only maintain sufficient contact to monitor patients 
for even the slightest side effects, but approach each individual 
from the prospective that the lowest possible dosage should be 
achieved once the patient has stabilized, while periodically at-
tempting to discontinue the medication altogether thereafter. 
Medication regulation should be able to foster this goal through 
quality of care monitoring. 
Board and care homes and nursing homes are only two iso-
lated environments illustrating that negligent and sometimes 
abusive use of antipsychotic drugs can occur in the private prac-
tice of medicine. However, given the apparent inevitability of 
these drugs to produce side effects, and their great potential to 
be inappropriately prescribed, legislative action designed to min-
imize their misuse in all areas of private medicine is essential. lUI 
Legislatively imposed regulations concerning the use of antipsy-
chotic drugs would help insure a responsible level of medical and 
staff practice in administration of these drugs, as well as protect 
individuals receiving these drugs from needlessly assuming the 
risk of their side effects. The following analysis will address the 
propriety of state intervention in the prescribing of antipsy-
chotic drugs, and propose one possible form of legislative action 
to help remedy the problem of their misuse. 
III. ANALYSIS 
Regulating the use of antipsychotic drugs in the area of pri-
vate practice of medicine, will surely trigger an uproar among 
psychiatrists and other physicians working in the mental health 
profession, in view of the medical profession's general aversion 
toward legal intervention in the practice of medicine. lIS Thus, it 
115. The inability to ascertain the actual extent these drugs are inappropriately pre-
scribed should not be a barrier to legislative action. The court addressing the reasonable-
ness of externally imposed regulation implemented to deter the misuse of dangerous 
drugs (Le., drugs which are addictive) relied on an earlier Supreme Court decision which 
stated: "[f]rom the beginning of civilized societies, legislators and judges have acted on 
various unprovable assumptions . . . . Nothing in the Constitution prohibits a state 
from reaching ... a conclusion and acting on it legislatively simply because there is no 
conclusive evidence or empirical data." Whalen v. Roe, 429 U.S. 590, 597, 598, n.21 
(1977) (quoting Paris Adult Theatre T. v. Slaton, 413 U.S. 49, 61, 63 (1973)). 
116. Although opposition to restrictions would also arise among other individuals 
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is necessary to evaluate any proposed regulation with respect to 
the physician's right to practice medicine free from unwarranted 
state interference. 
The state has a profound interest in seeing that medical 
procedures are performed under circumstances insuring maxi-
mum safety for the patient. ll7 Regulations of all professions con-
cerned with health is an acknowledged, legitimate function of 
the state's police power. llS Thus, the issuance of a state license 
to practice medicine is not an absolute right to practice medicine 
free of reasonable restrictions. 119 
working with the mentally ill, this discussion will be limited to licensed physicians, be-
cause they are the persons authorized to write or issue prescriptions. See CAL. HEALTH & 
SAFETY CODE § 11150 (West 1975); CAL. Bus. & PROF. CODE § 4036 (West 1985). If the 
controversy which is continuing over recognizing that involuntary mental patients have a 
right to refuse is any indication, unwelcome legal intrusions on the private practice of 
medicine will be attacked. The American Psychiatric Association, through its council on 
Psychiatry and Law, recently issued a statement reflecting "serious misgivings" about 
the Jamison standards (see supra note 11) stating: 
We believe that a proper approach to the basic question of the 
right to refuse medication should begin with the recognition 
that antipsychotic medication has proven to be a highly effec-
tive, and often essential treatment for patients who require in-
voluntary psychiatric hospitalization. The proposed guidelines 
by contrast, reflect a harsh view of the appropriateness of this 
form of treatment, relegating it instead to 'last resort' status 
.... To approach the question of medication as though it 
were only a threat to individual liberty seems to us unjustified 
and misguided. 
APA Decries Jamison Standards, 8 MENTAL & PHYSICAL DISABILITY L. REP. 496, 496 
(1984). See generally, Feldman, The Legal Restraints on Psychiatric Care, in LEGAL 
MEDICINE 1980 221-27 (C. Wecht ed. 1980) and Brooks, supra note 2, at 179, 212 for 
further examples of disapproval of legal intervention in the practice of psychiatry. 
117. Roe v. Wade, 410 U.S. 113, 150 (1973); Aden v. Younger, 57 Cal. App. 3d 662, 
679, 129 Cal. Rptr. 535, 545 (1976). 
118. Barsky v. Bd. of Regents, 347 U.S. 442, 449 (1954). Police power has been de-
fined as the "power inherent in a government to enact laws within Constitutional limits 
to protect the order, safety, health, morals and general welfare of society." Blinder v. 
State Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174, 179, 101 Cal. Rptr. 
635, 638 (1972) (quoting In re Rameriz, 193 Cal. 633, 649-50, 226 P. 914, 921 (1924)). 
This interest in the public health, safety and welfare has justified the licensing of physi-
cians (CAL. Bus. & PROF. CODE § 2000 et seq.), regulations of conditions within medical 
treatment facilities (CAL. HEALTH & SAFETY CODE § 1400 et seq., CAL. WELF. & INST. CODE 
§ 11000 et seq.), and regulation of pharmaceuticals (CAL. HEALTH & SAFETY CODE § 1100 
et seq.). Aden v. Younger, 57 Cal. App. 3d 662, 674, 129 Cal. Rptr. 535, 542 (1976) (citing 
these codes as examples of the proper exercise of police power). 
119. Blinder v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174, 
182, 101 Cal. Rptr. 635, 640 (1972); see Barsky v. Bd. of Regents, 347 U.S. 442, 451 
(1954). 
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Although physicians are granted certain privileges respect-
ing the administration of drugs,120 this privilege is limited where 
harm from their use or misuse is readily forseeable.l2l Accord-
ingly, a state's broad police power extends to regulating the ad-
ministration of such drugs by health professionals.122 
A state's police power to enact legislation in the areas of 
health and safety, is not without constitutional limitations.123 
Regulations limiting certain fundamental rights may be justified 
only by a compelling state interest.124 Although the right of pri-
vacy, founded in the fourteenth amendment's concept of per-
sonal liberty and restriction upon state action, has been declared 
a fundamental right,l2li a physician's right to privacy in his/her 
practice of medicine is not implicated under this constitutional 
protection. 126 Therefore, unless legislative regulation infringes 
120. Blinder v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174, 
182, 101 Cal. Rptr. 635, 640 (1972). 
121. See Minnesota ex rei Whipple v. Martinson, 256 U.S. 41, 45 (1921) where the 
court upheld a California statute regulating morphine on the basis that there was no 
question of authority of the state in the exercise of its police power to regulate the ad-
ministration, sale, prescription and use of dangerous and habit-forming drugs; Whalen v. 
Roe, 429 U.S. 589,603 n.30 (1977) where the court upheld a New York statute regulating 
dangerous, legitimate drugs (drugs which have both lawful and unlawful market) such as 
opium and opium derivatives, cocaine, methadone, and amphetamines, requiring all pre-
scriptions for these drugs be made out in triplicate and one copy be forwarded to the 
state; Blinder v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174, 181, 
101 Cal. Rptr. 635, 639 (1972) where the court upheld California statutes providing for 
treatment of narcotic addicts as a proper exercise of police power; People v. Privitera, 23 
Cal. 3d 679, 709, 591 P.2d 919, 926, Sup., 153 Cal. Rptr. 431, 438 (1979) where the court 
upheld a California statute making the sale, prescribing or administering of any unap-
proved drug intended for the alleviation or cure for cancer (e.g., laetrile) a misdemeanor. 
122. See, e.g., Minnesota ex rei Whipple Martinson, 256 U.S. 41, 45 (1921); Blinder 
v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174,181,101 Cal. Rptr. 
635,639 (1972); People v. Privitera, 23 Cal. 3d 697, 705, 591 P.2d 919, 923, Sup., 153 Cal. 
Rptr. 431, 435 (1979). 
123. Blinder v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174, 
180, 101 Cal. Rptr. 635, 638 (1972). 
124. Roe v. Wade, 410 U.S. 113, 155 (1973). 
125. Id. at 152-55. 
126. Cases which may be characterized as protesting "privacy" have involved two 
different kinds of interest: 1) an individual interest in avoiding disclosure of personal 
matters, and 2) an interest in making certain kinds of important decisions. Whalen v. 
Roe, 429 U.S. 589, 599-600 (1977). An asserted privacy interest involving professional 
judgment, such as the case in prescribing anti psychotics, is more akin to the second in-
terest. However, the kinds of "important decisions" recognized by the court as falling 
within this category of right to privacy involve "matters relating to marriage, procrea-
tion, contraception, family relationships, and child rearing and education." Id. at 600 
n.26 (quoting Paul v. Davis, 424 U.S. 693, 713 (1976)). Thus, decisions involving medical 
treatment are not covered in these kinds of right to privacy cases. People v. Privitera, 23 
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upon a fundamental right belonging to the patient, the state's 
justification in interposing its authority on behalf of the public 
is viewed under the rational basis standard.127 Furthermore, 
when danger to health exists, state regulations encroaching upon 
a patient's right to privacy are also tested under the rational ba-
sis standard.128 In that the state may properly assert a legitimate 
interest in safeguarding health by maintianing medical stan-
dards which insure maximum safety for the patient, the privacy 
right of the patient cannot be said to be absolute. 129 
Since there is no recognized fundamental right involved in 
the practice of medicine, and no absolute right to privacy be-
longing to the patient because of the danger to health antipsy-
chotic drugs present, state regulations on the prescribing of anti-
psychotic drugs will be considered under a rational basis 
standard. The patient's right to privacy, however, will also be 
addressed to determine the extent such regulations may prop-
erly be asserted by the state in conflict with this right. 
In applying the rational basis test, the courts have inquired 
(1) whether the interests of the public require such interference; 
and (2) whether the means used would be reasonably necessary 
for the accomplishment of that purpose, taking into considera-
tion whether these means are unduly oppressive upon 
individuals.130 
The state has a legitimate interest in maintaining medical 
standards so as to reduce negligent and abusive use of antipsy-
Cal. 3d 697, 702, 591 P.2d 919, 922, Sup., 153 Cal. Rptr. 431, 434 (1979). Furthermore, 
any right to privacy physicians have in the doctor-patient relationship is derivative from, 
and therefore no stronger than, the patient's. Whalen, 429 U.S. at 604. See infra notes 
128, 129 and accompanying text for a discussion of the patient's right to privacy. 
127. People v. Privitera, 24 Cal. 3d 697, 703, 592 P.2d 919, 922, Sup., 153 Cal. Rptr. 
431, 434 (1979). 
128. Roe v. Wade, 410 U.S. 113, 163 (1973); People v. Privitera, 23 Cal. 3d 697, 703, 
591 P.2d 919, 922, Sup., 153 Cal. Rptr. 431, 434 (1979). 
129. Roe v. Wade, 410 U.S. 113, 153-54 (1973). Although the court held the decision 
to have an abortion falls within the right to privacy, the court also acknowledged state 
regulations in areas protected by that right were appropriate. Accordingly, a woman's 
decision whether to terminate her pregnancy were limited by State regulations requiring 
abortions be performed at licensed institutions, and by licensed physicians. [d. at 163-65. 
The State's legitimate interest in the health of the mother also limited her right to ter-
minate her pregnancy only to the end of the first trimester of the pregnancy. [d. at 163. 
130. Blinder v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 174, 
179, 101 Cal. Rptr. 635, 638-39 (quoting Lawson v. Steel, 152 U.S. 133, 137 (1894)). 
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chotic medication and to minimize the number of patients ex-
posed to the inherent risks of these drugs,131 regardless of 
whether such practices are occurring in the public or private sec-
tor of medicine. Consequently, the interests of the public require 
that the state exercise its police power to protect the health and 
safety of its citizens.132 Implementing some form of prescription 
regulations to establish medication guidelines, would undoubt-
edly have a reasonable relationship to the achievement of this 
state interest, because such regulations could reasonably be ex-
pected to have a deterrent effect upon inappropriate medication 
practices. However, before assessing the oppressiveness of state 
regulation and the nature of the patient's privacy right involved, 
it is necessary to first propose a working model of a legislatively 
imposed system regulating prescriptions at antipsychotic drugs. 
One possible way for the state to attempt some form of reg-
ulation regarding the prescribing of anti psychotics is to develop 
regional computerized drug ordering systems which establishes 
and maintains drug records for each patient prescribed antipsy-
chotic drugs. Under this system, the physician would be re-
quired to send a copy of a standarized prescription form to the 
state for every prescription of antipsychotic drugs. Thus, the 
state would have access to the necessary data to determine and 
regulate the use of these drugs. Several authors133 have proposed 
such a computerized drug ordering system in which active and 
historic drug information, including drug name, dosage per ad-
ministration, frequency, physician name, and cancellation infor-
mation could be stored in each patient's computer record. Built 
into this drug ordering system would be a core drug formulary of 
clinical guidelines for antipsychotic drug prescriptions, so that 
when each new drug order for a patient is entered into the com-
puter, it is automatically reviewed against these guidelines scan-
ning all other active drug orders and relevant information about 
the patient (which would be required by the physicians to pro-
vide either on the' initial prescription form at the onset of drug 
treatment or on continuing prescription forms). Thus, the medi-
cation review system could check for inappropriate combinations 
of drugs, and inappropriate dose levels (doses generally above or 
131. For a discussion of inherent risks see supra notes 33-64 and accompanying text. 
132, See supra note 118 and accompanying text. 
133. Laska, Siegel & Simpson, supra note 19. 
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below a clinically acceptable range, and dose ranges for specific 
patient subgroups [e.g., children, adults, or elderly patients]). 
Those orders that are considered exceptions to guidelines, would 
generate exception reports. These exception reports, created by 
the computer, would then be sent back to the prescribing physi-
cian, indicating a justification report is necessary before pre-
scriptions will be continued to be filled as originally prescribed 
(the physician's justification could accompany the original pre-
scription form to avoid this step). These justifications may then 
be added to the patient's computer record. Once such a system 
appears workable, other areas of drug prescribing could be 
added to the system (i.e., extended drug exposure without an 
indication that attempts have been made to reduce dosage, and 
evaluation of side effects).IS4 
Although such a system would in no way guarantee against 
continuing misuse of these drugs,ISII it does alert the physician to 
possibly inappropriate drug regimens. Assuming that most phy-
sicians overprescribe these drugs without any bad intentions, 
such a computerized drug-review system would be invaluable as 
a clinical tool enabling periodic review of a patient's complete 
drug history. Also the mere fact that a physician knows he must 
account for his prescriptions by way of reply to exception re-
ports, will help reduce inappropriate drug practices.136 
The implementation of such a computerized drug review 
system as a form of regulation does not appear to be unduly op-
pressive to physicians. ls7 In so far as regulations serve only to 
134. See id. for further detail on how such an automated review system is organized 
and procedurally utilized. 
135. As with any type of external regulation, the possiblity always exists there will 
be those physicians and psychiatrists who may attempt to circumvent the regulation. 
One sociologist has observed: "Most rules are easily subverted in practice; when regula-
tions are imposed, efforts are often devoted to meeting their bureaucratic requirements 
without major impact on behavior; and the proliferation of regulation itself adversely 
affects morale and practice." Brooks, supra note 2, at 213. 
136. See supra note 24 indicating that the California county quality assurance sys-
tem which monitors a random lO% of the physician's caseload has proven sufficient in 
deterring inappropriate medication because the physician knows he/she is being 
monitored. 
137. However, from the viewpoint of staff who have strongly relied on these drugs in 
managing large numbers of patients in understaffed facilities, regulations limiting their 
ability to overmedicate patients may be unduly oppressive. However, staff convenience is 
beyond the legitimate use of these drugs, and thus such an argument is without merit. 
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prescribe excessive or other inappropriate prescribing, a physi-
cian's ability to practice medicine in accord with professional 
standards would not be impaired.13s Furthermore, regulatory 
schema would necessarily be designed to allow for justifiable ex-
ceptions.139 Therefore, at most, such regulations should entail no 
more than administrative paperwork which would not be consid-
ered unduly burdensome.14o Consequently, regulating the pre-
scription of anti psychotics would be a justifiable restriction on 
the right to practice medicine, given the rational basis test enu-
merated above has been satisfied. 
Regulations requiring physicians to disclose certain infor-
mation to the state about patients receiving antipsychotic drugs 
does not automatically entail an impermissible violation of the 
individual patient's right to privacy. Although these disclosures 
may reflect unfavorably on the character of the patient,14l such 
disclosures of private medical information would be indistin-
guishable from existing "invasions" of privacy associated with 
138. However, it can be argued that the passive, timid, and unsure physician may 
blindly conform to all guidelines, so as to avoid any entanglements with the authorities. 
Thus, such a drug ordering system may promote practicing medicine by the rules, rather 
than appropriately individualizing treatment to best meet the patient's needs. Laska, 
Siegel & Simpson, supra note 19, at 827. Although this may be a possible problem, the 
physician is free, nonetheless, to act in accordance with his/her professional experience 
and training, by virtue deviations from imposed guidelines only has to be justified. See 
infra note 148 and accompanying text concerning justifiable exceptions. 
Not only does each individual's physiology determine the specific pharmacological 
effects on antipsychotic drugs, but numerous "non specific" factors also play an impor-
tant role in their therapeutic effects. These include the race, age, and sex of the patient; 
the intellectual, emotional, and psychodynamic aspects of the patient's personality; the 
patient's attitudes and expectations about treatmnt, as well as the treating staff or phy-
sician, and the therapeutic setting. Cole, supra note 26, at 57. Thus, taking into consider-
ation these differing physiological and "non specific" factors, justifiable exceptions to the 
guidelines are inevitable, and are to be expected. 
139. See supra note 133 and accompanying text. 
140. See Blinder v. State, Dept. of Justice, Div. of Narc. Enforce., 25 Cal. App. 3d 
174, 180-81, 101 Cal. Rptr. 635,639-40 where the court held that statutes regulating the 
treatment of narcotic addicts were not unduly oppressive although they restricted the 
amount of methadone which may be given and limited locations where treatment could 
be administered. 
141. A previous or existing diagnosis of "mental illness" unquestionably has a stig-
matizing effect making an individual who has received, or is receiving antipsychotic 
drugs, extremely vulnerable in our society. Such an individual may be reproached and 
treated with caution, unnecessary concern, or avoidance by many employers or other 
people in interpersonal situations. See generally, J. ROBITSCHER, supra note 74, at 230-42 
for a discussion of the stigmatization and discrimination as the result of being diagnosed 
"mentally ill." 
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many facets of health care.142 
As mentioned above, when there exists a danger to health, 
the state's legitimate interest in the health and safety of its citi-
zens "supercedes" the privacy right of the individual patient.143 
Therefore, state regulations enacted to protect the safety, health 
and welfare of society are only required to bear a reasonable re-
lationship to the accomplishment of that purpose. 
Nonetheless, legislative enactments and administrative pro-
cedures implementing a drug monitoring system could safeguard 
against unwarranted public disclosures. 14. Such protective mea-
sures would help insure that information disclosed by physicians 
is available only to a small number of public health officials with 
a legitimate interest in the information for protection of the 
community from apparent abuse and negligent misuse of anti-
psychotic drugs. 1411 
Opponents to regulating the prescribing of antipsychotic 
drugs may assert that patients in the private realm of medicine 
have voluntarily given their informed consent to such treat-
142. Disclosure of private information to other doctors, hospital personnel, insur-
ance companies, and to public health agencies is a common occurrence in modern medi-
cal practice. Whalen v. Roe, 429 U.S. 589, 602 (1977). Examples of existing statutory 
reporting requirements are those relating to venereal disease, child abuse, injuries caused 
by deadly weapons, certifications of fetal death, and treatment of narcotic addicts. [d. at 
n.29. See CAL. HEALTH & SAFETY CODE §§ 11215-11221 (West 1975 & Supp. 1984) for 
statutory requirements concerning treatment for addiction. 
143. See supra note 29 and accompanying text. 
144. Public disclosure of any patient information could be prohibited by a statute 
with accompanying penalties for violations sufficient to deter any health department em-
ployee from failing, either deliberately or negligently, to maintain proper security. The 
legislature could also consider the need to enumerate the extent of physician-patient 
evidentiary privileges to protect stored data from being offered into evidence in any judi-
cial proceedings involving a patient or a doctor. See Whalen v. Roe, 429 U.S. 589, 600-02 
(1977) for further discussion on preventing public disclosure of patient information. 
145. Arguably, there will always exist a threat to privacy implicit in the accumula-
tion of personal information in computerized data banks or other government files. The 
collection of taxes, distribution of welfare and social security benefits, supervision of 
public health, and information kept by the Armed Forces are just a few examples of 
personal information in computerized data banks which is potentially embarassing or 
harmful if disclosed. [d. at 605. However, proper security measures in the utilization of 
such computerized systems have been held to be sufficient in guarding against an inva-
sion of the constitutionally protected right to privacy, provided that a legitimate state 
interest exists to justify the disclosure of private medical information. [d. at 606. Aden v. 
Younger, 57 Cal. App. 3d 662, 683, 129 Cal. Rptr. 535, 549 (1976). 
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ment,l.6 and thus if medication is being inappropriately pre-
scribed, the professional tort doctrine of malpractice is available. 
This conclusion, however, is based on erroneous assumptions. 
The first being the extent to which this consent is in fact 
voluntary. 
Individuals with psychosis (e.g., schizophrenia) often exhibit 
psychotic behavior periodically, rather than continuously.147 Pa-
tients who may fear "going crazy" or who are experiencing delu-
sions, hallucinations, overbearing irrational fears, or who are ob-
sessed with the idea that they are about to decompensate and do 
some injury, are greatful for anything that can relieve these 
frightening symptoms. It is under these circumstances a patient 
consents, arguably unable to contemplate which is worse, the ill-
ness itself or the side effects of the medication.u8 Furthermore, 
patients who do not want these medications may be pressured 
into taking medications for fear of having to return to the hospi-
tal. 149 In the case of board and care residents, admission into 
these facilities is often contingent upon continuing the residents' 
drug regimens. 15o Elderly nursing home patients are often so in-
stitutionalized,l5l that they are even less apt to refuse their med-
ication.152 Thus, to consider the consent "voluntary" is some-
what misleading. 
A second erroneous assumption is the availability of a suc-
146. For purposes of this discussion it will be assumed that the patient has been 
fully informed of all potential side effects. 
147. L. SEIDEN & L. DYKSTRA, supra note 3, at 198. 
148. Brooks, supra note 2, at 191. 
149. Some patients are discharged from the hospital or are treated initially as out-
patients on the contingency that they will continue their medication. Failure to show up 
for medication (i.e., fluphenazine injection) on the appointed day, can result in being 
returned to the hospital. Therefore, the threat of rehospitalization can pressure a person 
into taking his medication. J. ROBITSCHER, supra note 74, at 91. 
150. Telephone interview with Mal Branstein, Chairman of Residential Services 
Committee of Northern California Psych. Society (Nov. 16, 1984). Although board and 
care operators are not allowed to evict a person for refusing to take his or her medica-
tion, they do interview prospective boarders, having complete discretion to turn away 
any individual they fear may not comply with their medication regimen. [d. 
151. See supra note 26 for discussion of the syndrome of institutionalism. 
152. It is also important to consider that the emotion and cognitive dampening, and 
apathy induced by these drugs (see supra notes 65-68 and accompanying text) may limit 
any chronic patient's ability to later determine on one's own to discontinue drug ther-
apy, choosing to go against a psychiatrist's or physician's judgment, particularly when 
that individual has grown to respect and trust the physician. 
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cessful malpractice suit. Malpractice may be difficult to prove 
except in grossly negligent situationslll3 due to problems of cau-
sationlll4 and the fact that side effects occur even if medication is 
responsibly and competently prescribed. 1IIII Most importantly, 
however, malpractice recovery is only a remedy, offering no pre-
ventive protectionlll6 and entirely incapable of making the af-
flicted plaintiff truly "whole." 
One final and important consideration in support of legisla-
tively imposed regulations, is the distinguishing ability of anti-
psychotic drugs to alter the thinking process, personality, and 
behavior patterns of the patient, as opposed to other prescrip-
tion drugs having adverse side effects if misprescribed. There-
fore, conceivably surpassing the degree of the state's interest in 
limiting the number of individuals risking irreverisble neurologi-
cal injury, which can occur without warning and without regard 
to length of drug exposure,11l7 is the state's interest in protecting 
patients from unwarranted intrusions into their mental proces-
sess.1llS Unlike other areas of medical treatment utilizing medica-
tions which may inadvertently alter or reduce the function of 
one organ or another to improve its effectiveness/1I9 the thera-
peutic aim of antipsychotic drugs is to alter brain function, pro-
portionately reducing the individual's capacity to function as a 
person by blunting emotions, deadening memory and the ability 
153. See Clites v. State of Iowa, 322 N.W.2d 917 (Ct. App., Iowa 1982) and 
Faigenbaum v. Oakland Medical Center, No. 79-904-736 (Wayne County Cir. Ct. N.M., 
July 27, 1982). In both cases there was a failure to diagnose the plaintiff's severe tardive 
dyskinesia, and antipsychotic treatment was continued without the patient's or family's 
consent. See Wettstein & Appelbaum, Legal Liability for 7'ardive Dyskinesia, 35 HOSPI-
TAL & COMMUNITY PSYCHIATRY, 992-93 (1984) for a discussion of these two cases. 
154. E.g., since the typical development of tardive dyskinesia occurs after treatment 
with antipsychotic medication over an extended period of time, oftentimes a patient in 
the community has been treated by several different physicians in different facilities, 
making it difficult to hold any specific physician responsible. Wettstein & Applebaum, 
supra note 153, at 993. See also supra note 71 concerning the difficulty of the expert 
physician to offer definite conclusions. 
155. See supra note 13. 
156. Although litigation, in theory, should provide an incentive to physicians to 
comply with sound clinical practices, the fact that the irreversible damage of tardive 
dyskinesia typically occurs over an extended period of time during which the patient has 
been prescribed these drugs by perhaps several physicians, dissipates such an incentive. 
Id .. 
157. See supra notes 13 and 48-50. 
158. Aden v. Younger, 57 Cal. App. 3d 662, 678, 129 Cal. Rptr. 435, 545-46 (1976). 
159. E.g., some cardiac medications weaken the heart muscle so as to prevent ar-
rhythmias. P. BREGGIN, supra note 2, at 159. 
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to reason, and diminishing motivation.160 The individual be-
comes less able to think and feel, deprived of the power to con-
trol one's mind. In this respect, antipsychotic drugs lack a mean-
ingful distinction from psychosurgery and electroconvulsive 
therapy (ECT).l61 California has acknowledged that the consti-
tutionally protected right to privacy clearly includes privacy of 
the mind, as well as the essential right to be free in the exercise 
of one's own thoughts. 162 Accordingly, California has regulated 
conditions under which psychosurgery and shock treatment can 
be performed, requiring that all other treatments must be ex-
hausted and that such treatment is critically needed.163 Al-
though these forms of treatment are administered less fre-
quently and considered more controversial than antipsychotic 
drugs,164 the fundamental rights of patients do not cease to exist 
because drug therapy has become such an established mode of 
treatment within the field of psychiatry. Neither do these rights 
cease the moment a patient "voluntarily" consents. 1611 Any pa-
tient needlessly receiving these drugs, whether it be the conse-
quence of a physician's failure to monitor the continuing neces-
sity of treatment or abusive administration for management 
purposes, is divested of perhaps the most sacred privileges in 
our society-freedom of thought and expression of individuality. 
IV. CONCLUSIONS 
The state has a profound interest in preventing unnecessary 
160. See supra notes 65-68 and accompanying text. 
161. Whereas the danger of psychosurgery, and to some extent ECT, revolves 
around such treatment's irreversible alteration of the brain, similar chemically induced 
effects of antipsychotic drugs remain only as long as treatment is continued. However, 
the chronic individual maintained on antipsychotic drugs beyond their clinical usefulness 
is in reality experiencing the same deprivation of self-awareness and self-determination. 
See Aden v. Younger, 57 Cal. App. 3d 662, 671-72, 129 Cal. Rptr. 535, 541 for a discus-
sion of the hazards of psychosurgery and ECT. 
162. [d. at 679, 129 Cal. Rptr. at 546. 
163. See CAL. WELF. & INsT. CODE §§ 5000-5404.1 (West 1975). Although the court 
held that the terminology "critically needed" was an unconstitutionally vague criterion, 
the probable legislative intent was interpreted as requiring a "compelling need for these 
forms of treatment beyond the mere existence of a behavioral or mental disorder." Aden 
v. Younger, 57 Cal. App. 3d 662, 678, 129 Cal. Rptr. 535, 545 (1976). 
164. Aden v. Younger, 57 Cal. App. 3d 662, 680, 129 Cal. Rptr. 535, 547 (1976). 
165. See id. at 683, 129 Cal. Rptr. at 548-49 where the court addressed the intrusive 
and hazardous nature of psychosurgery, holding that substantive review of the treating 
physician was constitutional although the patient had voluntarily consented to the 
surgery. 
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administration of hazardous and intrusive treatment.166 Antipsy-
chotic drugs, clearly both hazardous167 and intrusive,168 are fre-
quently prescribed for other than their legitimate medical use, 
or without clinical necessity. Although only nursing homes and 
board and care homes have specifically been addressed, there is 
reason to suspect this is a health concern in private hospitals 
and institutions as well, given widespread use of these drugs 
within the medical profession.169 Properly drafted legislative reg-
ulation of the prescription of antipsychotic drugs enforcing com-
pliance with clinically approved guidelines would allow the con-
tinued use of this treatment when appropriate, while curbing 
their negligent misuse and abuse. 
Andrew Goode* 
166. Aden v. Younger, 57 Cal. App. 3d 662, 680-81, 129 Cal. Rptr. 535, 547 (1976). 
167. See supra notes 44-64 and accompanying text. 
168. See supra notes 65-69 and accompanying text. These drugs are intrusive in 
that they can change thinking processes, personality, and behavior patterns whether the 
patient given these drugs likes it or not. 
169. See supra notes 3, 20 and 23. 
* Golden Gate University School of Law, Class of 1986. 
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